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Autoreactive CD4+ T cells initiate the autoimmune disease Type-1 diabetes 
(T1D). Expression of DQ2, DQ8, and DQ2/8 trans-dimers are highly prevalent in T1D. 
However, the underlying molecular mechanisms are poorly understood. HLA-DM is 
essential for editing peptides bound to Major Histocompatibility Complex class II 
(MHCII) on antigen presenting cells, thus influencing the repertoire of peptides 
mediating selection and activation of CD4+ T cells. Here we explore the structural 
characteristics of DQ and the role of DM function, as well as the potential molecular 
mechanism of DM editing, as they may contribute to an understanding of autoreactive 
CD4+ T cell development in T1D. 
Cells coexpressing DM with these DQ molecules were observed to express 
elevated levels of class II-associated invariant chain peptides (CLIP), consistent with 
HPLC-MS/MS analysis of eluted peptides. Assays with purified recombinant soluble 
proteins further confirmed that T1D-associated DQ2 and DQ8 are resistant to DM 
editing. DM sensitivity was enhanced in mutant DQ8 with disruption of hydrogen bonds 
(H-bonds) that stabilize DQ8 near the DM-binding region.  
Compared to T1D nonassociated DQ1 and DQ6, the percentages of shared 
peptides among T1D-associated DQ molecules were significantly higher. Predicted 
peptide binding motifs of T1D-associated DQ molecules shared charged anchor residues, 
  
iv 
while hydrophobic anchors were present in DQ6 peptides. Competition binding assays 
and peptide dissociation rate measurements indicated that peptide with high affinity is 
necessary but not sufficient for DM editing resistance. DM editing dominates the stability 
of MHCII/peptide complexes in the cellular environment.  
DM catalyzes peptide exchange in MHCII through a mechanism that has been 
proposed to involve the disruption of specific conserved H-bond in MHCII/peptide 
complexes. HLA-DR1 molecules with alanine substitutions at each of the six conserved 
H-bonding positions were expressed in cells, and susceptibility to DM editing was 
evaluated by measuring the release of CLIP. Our results support the conclusion that no 
individual component of the conserved H-bond network plays an essential role in the DM 
catalytic mechanism.  
Taken together, our data support that the relative DM resistance in T1D-
associated DQ molecules affects the peptide repertoires and preferential presentation of 
T1D-associated autoantigenic peptides may contribute to the pathogenesis of T1D. 
 
To Qin, Angela and Andy 
and 
In memory of my father and father-in-law
  
 
TABLE OF CONTENTS 
 
ABSTRACT...................................................................................................................... iii  
LIST OF FIGURES......................................................................................................... viii 
LIST OF TABLES.............................................................................................................. x 
ACKNOWLEDGEMENTS............................................................................................... xi 
Chapters 
1. INTRODUCTION........................................................................................................ 1 
 Introduction............................................................................................................. 2 
 MHCII Function in Antigen Presentation............................................................... 2 
 Molecular Mechanism of DM-mediated Peptide Editing and Its  
Potential Role in T1D.............................................................................................  2 
Structural Characteristics of T1D-associated DQ Molecules................................. 4 
The Development of T1D-associated Autoreactive T Cells................................... 4 
Conclusion............................................................................................................... 5 
References............................................................................................................... 5 
2. TYPE 1 DIABETES ASSOCIATED HLA-DQ2 AND DQ8 MOLECULES ARE 
RELATIVELY RESISTANT TO HLA-DM MEDIATED RELEASE OF 
INVARIANT CHAIN-DERIVED CLIP PEPTIDES................................................... 8 
 
 Summary................................................................................................................. 9 
 Introduction............................................................................................................. 9 
 Results................................................................................................................... 12 
Discussion............................................................................................................. 18 
Materials and Methods.......................................................................................... 23 
References............................................................................................................. 26 
3. PEPTIDOMIC ANALYSIS OF TYPE 1 DIABETES ASSOCIATED HLA-DQ 
MOLECULES AND THE IMPACT OF HLA-DM ON PEPTIDE  





 Introduction........................................................................................................... 52 
 Results................................................................................................................... 54 
Discussion............................................................................................................. 62 
Materials and Methods.......................................................................................... 65 
References............................................................................................................. 68 
4. HLA-DM FUNCTIONS THROUGH A MECHANISM THAT DOES NOT 
REQUIRE SPECIFIC CONSERVED HYDROGEN BONDS IN CLASS II 
MHC-PEPTIDE COMPLEXES................................................................................. 95 
 
Abstract................................................................................................................. 96 
 Introduction........................................................................................................... 96 
Materials and Methods.......................................................................................... 97 
 Results and Discussion.......................................................................................... 97 
Concluding Remarks............................................................................................. 99 
References............................................................................................................. 99 
5. DISCUSSION........................................................................................................... 101 
Overview............................................................................................................. 102 
 Role of Invariant Chain in MHC Class II Antigen Presentation Pathway.......... 103 
Role of DQ Molecules in Autoreactive CD4+ T Cell  
Development and Activation............................................................................... 105 




A. SUPPLEMENTAL DATA FOR CHAPTER 4......................................................... 121 
B. EFFECTS OF EXTRA HYDROGEN BONDS ON THE DQ8/PEPTIDE  




LIST OF FIGURES 
 
Figure 
1.1 Structure characteristics of DR1 and T1D sensitive, neutral, and  
protective DQ molecules................................................................................ 3 
 
1.2 Model of autoreactive CD4+ T cell development in T1D.............................  5 
 
2.1 DM editing sensitivity of Ii-derived CLIP peptides in T1D neutral  
DQ1, protective DQ6 or susceptible DQ2, DQ8 and DQ2/8  
trans-dimers.................................................................................................. 32 
 
2.2 Pattern of eluted unique CLIP peptides........................................................ 34 
 
2.3 Binding analysis of the ZnT8-derived ZnT8(126) peptide to purified  
 fDQ molecules eptides................................................................................. 36 
 
2.4 CLIP dissociation rate and DM catalytic potency measured with  
purified DQ molecules................................................................................. 38 
 
2.5 Impact of hydrogen bonds between the two helical regions of α and β  
chains near the P1 pocket of DQ8 molecule................................................ 40 
 
2.S1 N-terminus sequence of CLIP peptides and the specificity of  
 CerCLIP.1 mAb........................................................................................... 43 
 
2.S2 The expression of Ii, DQ and DM in 293T cells......................................... 45 
 
2.S3 DM editing effects of T1D associated DQ molecules on Ii-derived  
 CLIP peptides in T2 transductants............................................................... 47 
 
3.1 Peptidome analysis of T1D associated and non-associated DQ  
molecules with the peptides eluted from 293T transductants...................... 72 
 
3.2 Comparison of the peptide binding affinity among DM resistant,  
dependent and sensitive peptides by the measurement of IC50  
in peptide competition experiment............................................................... 74 
  
ix 
3.3 Peptide dissociation rates and DM editing effects on LEP147  
and CKA362 peptides.................................................................................. 76 
 
3.4 Effects of DM editing in different DQ-peptide complex stability............... 78 
 
3.S1 Distribution of the subcellular localization of proteins  
identified by the eluted unique peptides...................................................... 83 
 
3.S2 Distribution of the length of unique peptides that were  
detected from each DQ samples.................................................................. 85 
 
3.S3 The frequency of unique peptides that were identified in 
common between samples from different DQ molecules  
in the absence of DM editing....................................................................... 87 
 
3.S4 Predicted peptide binding motifs of each DQ molecules............................ 89 
 
3.S5 The classification of eluted peptides for their sensitivity to  
DM editing................................................................................................... 91 
 
3.S6 DM-catalyzed rate enhancements in DQ6/ABP625 complex..................... 93 
 
4.1 The conserved hydrogen bond network in class II  
MHC-peptide complex................................................................................ 97 
 
4.2 Effect of mutations in conserved positions in the DR1 α-chain  
on susceptibility to DM-mediated CLIP release.......................................... 98 
 
4.3 Effect of mutations in conserved positions in the DR1 β-chain  
on susceptibility to DM-mediated CLIP release.......................................... 98  
 
4.4 Effect of mutational disruption of DR1 β-chain hydrogen bonds  
on DM catalytic potency.............................................................................. 98 
 
A.1 Asparagine substitution at position 81 in the DR1 β chain does 
not affect susceptibility to DM-mediated CLIP release............................. 122  
A.2 Replacement of the histidine at position 81 in the DR1 β  
chain does not change the pH dependence of DM-catalyzed  
peptide binding........................................................................................... 124 
 
B.1 Effects of extra hydrogen bonds on DQ8/peptide complex  






LIST OF TABLES 
 
Table 
2.1 Eluted T1D-associated autoantigen-derived peptides with  
previously reported positive function in autoreactive CD4+ T cell  
activation assay............................................................................................ 42 
 
2.S1 T1D-associated auto-antigen derived peptides eluted from 293T 
transductants with or without DM expression............................................. 49 
 
3.1 Peptides with different DM sensitivity that were eluted from  
DQ6+Ii or DQ6+Ii+DM 293T cells............................................................. 80 
 
3.2 Half-life (t1/2) of DQ/peptide complexes in the absence or  
presence of DM and the peptide IC50 values.............................................. 81 
 
3.3 The intrinsic and DM mediated catalytic peptide dissociation rates........... 82 
 
4.1 Peptide dissociation rates for mutant DR1 molecules................................. 99 
 
B.1 The comparison of calculated peptide intrinsic dissociation  
rates (Kin) between DQ8 wild type and E86A mutation that  







This work would not have been accomplished without the support and 
contribution from so many individuals. First of all, I would like to thank Dr. Peter E. 
Jensen for providing me the opportunity to work with him in different roles in the past ten 
years. I thank him for providing a stimulating multidisciplinary environment and 
introducing me the field of immunology, which was new to me. I am also very grateful to 
him for the continuous support and guidance in my research and his confidence in me 
throughout the years, as well as his invaluable help and advice in my career.   
I would like to thank the members of my large and strong thesis advisory 
committee, including Drs. Peter E. Jensen, Gerald J. Spangrude, Julio C. Delgado, 
Matthew A. Williams, Ryan M. O’Connell, Attila Kumánovics, and Xiao He, for their 
continuous guidance, invaluable suggestions, and enthusiastic encouragement during my 
graduate career. In particular, I would like to thank Dr. Delgado for his tremendous help 
on my research project and career development. I am grateful to Dr. Kumánovics for his 
help and recognition in my career development. I am also grateful to Dr. Williams for his 
guidance of research and critical reading of the manuscript. Especially, I would like to 
thank Dr. Xiao He for his constant input in supporting my research and proofreading of 
the manuscript. He is also a close friend who provided massive help in my life.  
  
xii 
I want to thank Dr. Alan L. Rockwood for his help on the analysis of peptidomes 
of T1D associated DQ molecules. I would like to thank Dr. Kuan Y. Chang for the 
prediction of peptide binding motifs of T1D associated DQ molecules. I am also grateful 
to Dr. Adam P. Barker for his massive resources, and continuous technical support and 
advice. In addition, I would like to give my thanks to Dr. Mathew F. Cusick for his help 
on providing human B cell lines and especially for peripheral blood samples.  
I am very grateful to all the former and current members of the Jensen lab. I have 
considerable gratitude to Dr. Lisa M. Reed-Loisel for her kind help and technical training 
in the beginning of my research; thanks to Dr. Kari A. Callaway for her contribution to 
the DM mechanism project and to the building of Fluorescence Polarization platform; 
thanks to Hernando Escobar for his help in identification of the eluted peptides by HPLC-
MS/MS; thanks to Dr. Eugene V. Ravkov for his help on the techniques of MHC tetramer 
and lentiviral transduction; thanks to Hu Dai and Xiaomin Wang for their valuable help 
with my experiments. Especially, I would like to thank Eduardo Reyes-Vargas for his 
help in the elution of peptides from T1D-associated DQ molecules. He is also a perfect 
cofighter against the difficulties in our research on DM mechanism and a continuous 
source for invaluable academic discussions and language training. 
Furthermore, I would like to thank Allison Boyer, Kimberly Antry, Shannon 
Ritzman, and all administrative staff, especially the path-IT team. Their help made my 
study in the Department of Pathology much easier.  I am grateful to the Microbiology and 
Immunology Ph.D. Program for financial support during my graduate career. 
Last but not least, I would like to thank my family. Thanks to my two kids, 
Angela and Andy, for their love, with tears and smiles, and silliness, naughtiness, 
  
xiii 
smartness, happiness, plus their Swahili slogan “HAKUNA MATATA”. Especially, I 
would like to thank my beloved wife, Qin, for her rock solid support, endless love, and 





INTRODUCTION: STRUCTURAL CHARACTERISTICS OF 
HLA-DQ THAT MAY IMPACT DM EDITING AND  
SUSCEPTIBILITY TO TYPE-1 DIABETES 
 
Originally published in Frontiers in Immunology. Zemin Zhou and Peter E. Jensen. 2013. 
Structural characteristics of HLA-DQ that may impact DM editing and susceptibility to 































































published: 29 August 2013
doi: 10.3389/fimmu.2013.00262
Structural characteristics of HLA-DQ that may impact DM
editing and susceptibility to type-1 diabetes
Zemin Zhou and Peter E. Jensen*
ARUP Laboratories, Department of Pathology, University of Utah, Salt Lake City, UT, USA
Edited by:
Lawrence J. Stern, University of
Massachusetts Medical School, USA
Reviewed by:
Masaaki Murakami, Osaka University,
Japan
Justine Mintern,Walter and Eliza Hall
Institute, Australia
*Correspondence:
Peter E. Jensen, ARUP Laboratories,
Department of Pathology, University
of Utah, 15 North Medical Drive East
Suite 1100, Salt Lake City, UT
84112-5650, USA
e-mail: peter.jensen@path.utah.edu
Autoreactive CD4+T cells initiate the chronic autoimmune diseaseType-1 diabetes (T1D),
in which multiple environmental and genetic factors are involved. The association of HLA,
especially the DR-DQ loci, with risk for T1D is well documented. However, the molecular
mechanisms are poorly understood. In this review, we explore the structural characteristics
of HLA-DQ and the role of HLA-DM function as they may contribute to an understanding
of autoreactive T cell development in T1D.
Keywords: type-1 diabetes, HLA-DQ, HLA-DM, invariant chain, autoreactiveT cells, negative selection
INTRODUCTION
Multiple factors contribute to the chronic autoimmune disease
type-1 diabetes (T1D) characterized by selective destruction of
pancreaticb cells. To complementb cell deficiency, life-long insulin
replacement is required to maintain glucose metabolism. There
is evidence that both genetic and environmental factors con-
tribute to the etiology of T1D. Genome wide association analysis
data indicate that the highly polymorphic major histocompati-
bility complex (MHC), including both MHC class I and class II
(MHCI and MHCII), contributes approximately 50% of genetic
susceptibility to T1D (1). Individuals with MHCII DR3-DQ2 and
DR4-DQ8 haplotypes have a significantly higher risk of T1D
and DQ6 (DQA1⇤0102/DQB1⇤0602) is dominantly protective in
Caucasians, Mexicans, and other Latin American populations (1–
3). A number of studies have demonstrated the peptide-binding
specificity of DQ8 as well as T cells from T1D that recognize
pancreatic autoantigens presented by DQ8 (4–8). Compared with
theDQ2 andDQ8homozygous individuals,DR3-DQ2/DR4-DQ8
heterozygotes (DRB1⇤0301-DQA1⇤0501-DQB1⇤0201/DRB1⇤04-
DQA1⇤0301-DQB1⇤0302) have the highest risk in whites of Euro-
pean andNorthernAfrican decent (9). Haplotype sharing analysis
in siblings also shows that the risk forT1D is dramatically increased
in DR3/4-DQ2/8 siblings (10). Another study of 607 Caucasian
families and 38 Asian families further confirmed the association
of DQ2 and DQ8, especially the trans-dimer DQ2-8, with the
highest risk of T1D (11). These striking observations raise sev-
eral open questions: (a) what structural features distinguish DQ
molecules associated with risk for T1D; (b) why do heterozygotes
have even greater risk for T1D than individuals homozygous for
DQ2 or DQ8; (c) how do the autoreactive CD4+ T cells that
mediate b cell destruction develop and escape negative selection
in the thymus. In this review, we will focus on the function of
MHCIImolecules and their role in selection of autoreactive CD4+
T cells.
MHCII FUNCTION IN ANTIGEN PRESENTATION
In the adaptive immune system,MHCI andMHCIImolecules play
critical roles by presenting peptides on the surface of antigen pre-
sentation cells (APC) to select or activate CD8+ andCD4+T cells,
respectively (12). MHCI and MHCII share very similar structure
in the peptide-binding groove and both can load with endoge-
nous or exogenous peptides through two sets of non-covalent
interactions: sequence dependent anchor-pocket interactions and
conserved hydrogen-bond networks formed between the pep-
tide and non-polymorphic amino acids in MHC. However, the
peptide-binding groove of MHCII is open in both sides, com-
pared with the closed binding site in MHCI; therefore, MHCII
can present relatively longer peptides. Extra residues in the N -
terminus of the bound peptide, such as P-1 and P-2, are important
for the stability of MHCII/peptide complexes (13). MHCII mole-
cules initially assemblewith invariant chain (Ii) in the endoplasmic
reticulum (ER) and the peptide-binding groove is occupied by a
disordered region of Ii to prevent the loading of other ligands in
the ER.After translocation into late endosomal compartments, Ii is
processed by endosomal proteases and a segment of Ii, CLIP (class
II-associated Ii peptide),occupies the peptide-binding groove. The
dissociation of CLIP from the peptide-binding groove is necessary
for the loading of other peptides, which is accelerated by a non-
classical MHC class II molecule, HLA-DM (DM) (14). DM can
catalyze multiple subsequent rounds of peptide exchange, editing
the repertoire of presented peptides, and favoring the most stable
peptide complexes.
MOLECULAR MECHANISM OF DM-MEDIATED PEPTIDE
EDITING AND ITS POTENTIAL ROLE IN T1D
The general function of DM is well defined but many questions
have remained about its precise mechanism of action (14). The
possibility that DM selectively disrupts conserved hydrogen bonds
between peptide and MHCII had been proposed as a potential
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mechanism (15, 16); however, subsequent analysis of substituted
MHCII molecules with disrupted H-bonds ruled out this mech-
anism in its simplest form (17, 18). It has been suggested that
the interaction of DM with MHCII activates the empty or inac-
tive form of MHCII to be active for peptide loading (19, 20).
MHCII molecules with an empty P1 pocket can associate with
DM while the filled form has been reported to interact poorly
with DM (21). Molecular dynamics simulation studies indicated
that the peptide-binding groove in the bound, partially filled, or
empty states are significantly different (22–24), indicating that the
interaction of DM and MHCII might induce a conformational
rearrangement of peptide-binding groove, especially the a53–65
region around P1 pocket of MHCII (19). Recent advances with the
co-crystallization of DM and DR (25), and the co-crystallization
of DM and DO (26), another non-classical MHCII that inhibits
DM function (14), provide a significant advance in our under-
standing of the interaction of DM with MHCII, confirming that
DM binding is associated with a major structural rearrangement
of the MHCII a53–65 region (Figure 1A) that precludes occu-
pancy of the region of the peptide-binding groove that normally
accommodates the peptide N -terminus, including the P1 anchor
residue.
Genetic studies of the limited polymorphisms of DMa and
DMb in different populations indicate that specific DM alleles
are associated with T1D (27–29). Interestingly, patients with T1D
show relatively high levels of CLIP on the surface of lympho-
cytes (30), and T1D-like NOD mice also display high CLIP levels
(31), indicating that DM is inefficient in removing CLIP from
specific MHCII molecules expressed in individuals with T1D and
NOD mice. A natural deletion of arginine in a53 of DQ2 has
FIGURE 1 | Structure characteristics of DR1 andT1D sensitive, neutral,
and protective DQ molecules. (A)The structure of DR1 showing with P1
pocket empty (left of upper panel, in co-structure of DM-DR1), bound with
high affinity HA peptide (middle), and bound with low affinity CLIP (right).
The purple and cyan colors show the conformational difference of the two
helices near the P1 pocket of the DR1 peptide-binding groove in the crystal
structures. The lower panel shows the H-bond between 310 helix and
b-sheet, and the aW43 position (purple arrow “!”). The unique H-bond in
DR1-CLIP is showed by blue arrow “!”. (B) Conformational difference of the
310 helix, b-sheet, and inter-helix H-bond(s) in different DQ molecules. There
is a conserved H-bond formed in all of the DQ molecules and DR1 bound
with CLIP peptide (blue arrow “!”), indicating a similar status among these
molecules. Also, extra H-bond(s) are found in T1D-associated DQ2 and DQ8
(orange arrow “!”), suggesting a stabilized conformation in this region,
compared with DQ1 or DQ6. (C) Conformational differences in the a chain
310 helix, the b chain near the P1 helix, and the H-bond(s) interactions
between the two helices. DQ8 have 3 H-bonds formed between the two
helices, and DQ8-2 has 1 H-bond, compared with DQ1, DQ2, and DQ6, with
no H-bonds. (D) Sequence comparison of different DQ molecules and DR1
in the helix regions.
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been demonstrated to reduce affinity for DM, explaining inef-
ficient DM-mediated peptide exchange in T1D-associated DQ2
molecules (32, 33), further supporting the idea that inefficient
DM editingmay play a critical role in T1D-associated autoreactive
CD4+ T cell development (32, 34). The coincidence of high CLIP
expression might be a general indicator of poor DM editing func-
tion with T1D-associated DQ molecules, and it is also plausible
that high levels of CLIP select CD4 T cells are cross-reactive and
autoreactive. Interestingly, Ii deficient NOD mice are protected
from T1D (35), providing further evidence for the potential role
of CLIP in autoreactive T cell development; however, there is no
direct evidence currently supporting this hypothesis.
STRUCTURAL CHARACTERISTICS OF T1D-ASSOCIATED DQ
MOLECULES
The structure of the T1D sensitive, neutral, and protective DQ
molecules, including DQ2 (PDB ID: 1S9V) (36), DQ8 (1JK8,
2NNA, and 4GG6) (37–39), DQ8-2 (4D8P) (40), DQ1 (3PL6)
(41), and DQ6 (1UVQ) (42), have been recently solved. These DQ
molecules share the general structural characteristics of MHCII
with an open peptide-binding groove interacting with variable
length peptides through a nine-residue binding “core”. In the core,
preferred amino acids anchor the peptide at positions 1, 4, 6, 7, and
9 (32). However, the conformations of the 310-helix region (43),
which is in the DM-MHCII contact surface (25) and affects the
sensitivity of DM-MHCII interaction (43), are apparently variable
among the different DQ structures (Figures 1A,B). Interestingly,
there are 3 H-bonds formed between the two helices in the a and
b chains of DQ8 and 1 H-bond in DQ8-2, but no H-bond in the
low T1D risk DQ1 or DQ6molecules (Figure 1C). The conforma-
tion of the two helices and the number of inter-helix H-bonds in
DQ8 are not dependent on the sequence specificity of bound pep-
tide (37–39). Sequence comparison of the helical regions of the
a and b chains among these DQ molecules shows that, in T1D-
associated DQ2 and DQ8, the 310 helix of the a chain includes
several positively charged residues and the helix of the b chain has
some negatively charged or uncharged hydrophilic residues with
the potential to form H-bond(s); while in DQ1 and DQ6, those
residues are hydrophobic (Figure 1D). The structure differences
between DQ8 and other DQ molecules indicates that H-bond(s)
might play a role in regulation of the sensitivity to DM editing
by further stabilizing the DM contact region, providing an ener-
getic barrier to formation of the DM-bound conformation. The
structural differences between DQ8 and DQ2 suggest that differ-
ent mechanisms might be responsible for the relative inefficiency
of DM-mediated peptide editing in these molecules (33). The sen-
sitivity of the T1D-associated DQ8 and DQ8-2 molecules to DM
editing, and the potential inter-helixH-bond(s) or other structural
features that might impact DM catalytic potency warrant further
investigation.
It is still unclear why heterozygosity for DQ2/8 confers excep-
tionally high risk for T1D. APC in individuals with this haplo-
type co-express four distinct DQ molecules, including the trans-
encoded DQ2-8 and DQ8-2 mixed haplotype molecules and the
parental DQ2 and DQ8 proteins. Peptides eluted from the 293T
cells expressing different DQ molecules show that the peptide-
binding motifs of these DQ molecules are unique (8), supporting
the hypothesis that the trans-dimers in heterozygotesmight confer
risk through independent presentation of specific self-peptides
(44, 45). However, it is also possible that the higher risk of DQ2/8
heterozygous is due to an expanded repertoire of presented self-
peptides by the combination of four DQ molecules. A study
comparing gluten-specific T cells from Celiac disease patients
demonstrated the potential for T cells to cross-react with DQ8
and the DQ2-8 trans-dimer (46), raising the possibility that T
cell cross-reactivity might somehow contribute to the etiology
of autoimmunity associated with DQ2/8 heterozygosity. Further
studies are needed to explore these various possibilities.
THE DEVELOPMENT OF T1D-ASSOCIATED AUTOREACTIVE T
CELLS
A big challenge in this field is to understand how autoreactive T
cells develop, survive negative selection, and become activated to
mediate tissue damage. In the thymus, the autoimmune regula-
tor (Aire) regulates the ectopic expression of “tissue-restricted”
antigens in medullary thymic epithelial cells (mTECs). The fate
of thymocytes is determined by the affinity of expressed T cell
receptor (TCR) for self-peptide-MHC complexes (47). Theoreti-
cally, the T cell precursors that bind strongly to self-peptide-MHC
complex on thymic dendritic cells (DCs) and mTECs will be
deleted, and all remaining mature T cells are self-tolerant. How-
ever, the identification of autoreactive T cells in T1D patients, and
even in healthy subjects, indicates that negative selection in the
thymus is incomplete (48). Several mechanisms have been pro-
posed for inefficient deletion of autoreactive T cells in the thymus,
including differences in autoantigen expression in the thymus and
periphery, autoantigen posttranslational and posttranscriptional
modification, autoantigen polymorphisms (49), and mechanisms
through which key self-peptides can be presented on the cell sur-
face through alternative pathways (34), or as a result of poor DM
editing function (32). In addition, T cell cross-reactivity between
microbial and self-antigens may also play an important role in the
development of autoimmunity (50).
Based on current findings,we postulate that theT1D-associated
DQ molecules (DQ2, DQ8, and the DQ2/8 trans-dimers) share a
common feature, a relative resistance to DM-mediated peptide
exchange, and editing. This impacts antigen presentation in two
ways (Figure 2). A substantially increased fraction of MHCIImol-
ecules escape evenone roundof peptide exchange, resulting inhigh
levels of CLIP presentation in the periphery and presumably also
in the thymus. Secondly, a reduction in the efficiency of further
peptide editing may lead to presentation of an array of relatively
unstable peptide complexes. High levels of CLIP in the thymus
might result in positive selection of T cells that cross-reactive
with autoantigens in the periphery, or a reduction in the negative
selection of self-reactive T cells, as is seen in the extreme case in
mice with targeted deletion of DM (51). Increased presentation of
unstable self-peptide complexes might also lead to inefficient neg-
ative selection and survival of T cells with a capacity to be activated
in the periphery under conditionswhere the concentration of pan-
creatic b cell antigens is high. Alternatively, unstable complexes
may be more susceptible to DM-independent peptide exchange in
the periphery, promoting the activation of “type B” T cells that
recognize b cell peptides bound to MHCII through an alternative
register or conformation generated through alternative presenta-
tion pathways (34). These potential mechanisms may contribute
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FIGURE 2 | Model of autoreactive CD4+T cell development inT1D. In
the thymus, Aire regulates tissue-specific autoantigen expression.
Autoantigen peptides are processed in the late endosomal compartment
and loaded in the peptide-binding groove of MHCII by DM editing. In case of
inefficient DM editing, the pre-bound CLIP peptide may escape peptide
exchange, resulting high levels of CLIP presentation (1). Secondly, the
inefficient DM editing may lead to presentation of both low affinity and high
affinity peptides on the cell surface (2). The stable MHCII-peptide complex
will deliver strong signal through theT cell receptor (TCR) and induce the
deletion of CD4+T cells by negative selection, while the unstable
MHCII-peptide complex will deliver weak signal and this signal may induce
the positive selection of CD4+T cells. Alternatively, the unstable complexes
presented on the cell surface may be more susceptible to DM-independent
peptide exchange (3). Those escaped CD4+T cells will migrate into the
periphery and initiate the b cell destruction in pancreas under certain
conditions.
to the pathogenesis of T1D but further elements are needed to
explain the specificity for b cells as opposed to other tissues. This
is presumably related to the capacity of the T1D-associated DQ
molecules to bind and present key b cell self-peptides.
CONCLUSION
Type-1 diabetes is a chronic autoimmune disease affected by both
environmental and genetic factors. Themechanism(s) responsible
for the high genetic risk associated with HLA genotype, and
especially DQ2, DQ8, and DQ2/8 heterozygosity, remains poorly
understood despite the obvious role of these molecules in antigen
presentation. ReducedDMediting of T1D-associatedDQ-peptide
complexes combined with T cell cross-reactivity may contribute.
Further analysis of structural and functional characteristics that
distinguish disease-associated DQmolecules from neutral or pro-
tective alleles is likely to provide insights into the fundamental
question of why HLA haplotype is such an important factor in
determining risk for T1D.
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HLA-DM is essential for editing peptides bound to Major Histocompatibility 
Complex class II (MHCII), thus influencing the repertoire of peptides mediating selection 
and activation of CD4+ T cells. Individuals expressing HLA-DQ2 or DQ8, and DQ2/8 
trans-dimerss, have elevated risk for type 1 diabetes (T1D). Cells coexpressing DM with 
these DQ molecules were observed to express elevated levels of CLIP (Class II 
associated invariant chain peptide). Relative resistance to DM-mediated editing of CLIP 
was further confirmed by HPLC-MS/MS analysis of eluted peptides, which also 
demonstrated peptides from known T1D-associated autoantigens, including a shared 
epitope from ZnT8 that is presented by all four major T1D-susceptible DQ molecules. 
Assays with purified recombinant soluble proteins confirmed that DQ2-CLIP complexes 
are highly resistant to DM editing, whereas DQ8-CLIP is partially sensitive to DM, but 
with an apparent reduction in catalytic potency. DM sensitivity was enhanced in mutant 
DQ8 molecules with disruption of hydrogen bonds that stabilize DQ8 near the DM-
binding region. Our findings show that T1D-susceptible DQ2 and DQ8 share significant 
resistance to DM editing, compared with control DQ molecules. The relative resistance of 
the T1D-susceptible DQ molecules to DM editing and preferential presentation of T1D-
associated autoantigenic peptides may contribute to the pathogenesis of T1D.  
 
Introduction 
Type 1 diabetes (T1D) is an autoimmune disease characterized by selective 
destruction of pancreatic β cells. Multiple genetic and environmental factors have been 
implicated in the etiology of T1D. Among these factors, certain MHC haplotypes are 
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associated with a high risk for development of T1D, with a potential role of MHC 
molecules in the selection or activation of autoreactive T cells involved in T1D [1]. 
Genetic studies have implicated DQ2 (DQA1*0501/DQB*0201) and DQ8 
(DQA1*0301/DQB1*0302) as important risk factors. DQ2/8 heterozygotes, expressing 
two potential DQ trans-dimerss as well as DQ2 and DQ8, have a further elevation in risk. 
By contrast, DQ6 (DQA1*0102/DQB*0602) has a dominant protective effect, while DQ1 
(DQA1*0101/DQB1*0501) is neutral to T1D [2-8]. Beyond speculation, the mechanisms 
responsible for the disease risk associated with expression of specific MHC class II 
(MHCII) alleles remain to be established. 
MHCII molecules present endogenous or exogenous peptides on the surface of 
APC to select or activate CD4+ T cells in the thymus or periphery [9]. Classical MHCII 
are initially assembled with the class II invariant chain (Ii) chaperone protein. Ii is 
partially released through a series of successive proteolytic events in endosomal 
compartments, leaving a fragment, CLIP, occupying the peptide-binding groove. Antigen 
presentation is critically dependent on the release of CLIP and exchange with antigenic 
peptides sampled in endosomal compartments, which is catalyzed by a nonclassical MHC 
protein HLA-DM. DM functions optimally at acidic pH to catalyze CLIP dissociation 
and peptide exchange. It can catalyze multiple rounds of peptide exchange, and 
preferentially edit unstable peptide complexes, favoring the presentation of highly stable 
peptide complexes under physiological conditions. Thus, DM plays a critical role in 
editing the repertoire of peptides available for selection and recognition by CD4+ T cells 
[10, 11]. It has been noted that CD4+ T cells with specificity for self-peptides with low 
affinity for MHC can escape negative selection in the thymus [12-16].  The identification 
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of autoreactive CD4+ T cells recognizing low-affinity peptides in both nonobese diabetic 
(NOD) mouse [17-19] and human [20] autoimmune diabetes suggests the possibility that 
incomplete DM editing may contribute to presentation of a unique repertoire of peptides 
important to the pathogenesis of T1D.  
The recently published cocrystal structures of DM bound to the MHCII molecule 
DR1 demonstrate a major structural rearrangement in the region of the DR1 peptide-
binding groove that accommodates the N-terminal segment of bound peptide proximal to 
the DM contact surface [21]. This conformation change precludes full occupancy of the 
peptide-binding groove. Polymorphisms in DM contact residues have the potential to 
impact DM binding affinity and catalytic potency [22]. In addition, polymorphisms in 
MHCII that might impact the conformational stability in the region that undergoes a 
major structural transition might impact DM editing function [23]. The potential effects 
of MHCII polymorphism on susceptibility to DM editing have been explored to a limited 
extent. Notably, it has been reported that DQ2 is a poor substrate for DM, due to a natural 
deletion of arginine (α53) in the α chain of DQ2 [22, 24]. This allele is associated with 
celiac disease [25] as well as T1D. However, that naturally deleted residue of DQ2 is 
intact in DQ8, and the susceptibility of DQ8 to DM editing is unknown. Different 
mechanism(s) might be responsible for the association of DQ8 with increased risk for 
T1D. In addition to the obvious impact on peptide binding specificity, MHCII 
polymorphisms might contribute to the pathogenesis of CD4+ T cell autoimmunity by 
influencing a variety of steps in the peptide loading, editing, and presentation process, 
possibly enabling alternative mechanisms for presentation of key autoantigens or 
selection of autoreactive T cells [22, 26, 27].  
  
12 
Given the potential importance of DM in modulating the repertoire of peptides 
that mediate thymic selection and/or peripheral activation of autoreactive T cells in T1D 
[17, 18, 20], we investigated the sensitivity of the major T1D-susceptible DQ molecules 
to DM editing. We coexpressed DQ, Ii, and DM molecules in 293T cells to compare DM 
mediated release of Ii derived CLIP peptides. We found that DQ2, DQ8, or DQ2/8 trans-
dimerss were more resistant to DM editing than T1D-protective DQ6 or the T1D-neutral 
DQ1 molecules, as demonstrated by retention of CLIP. HPLC-MS/MS analysis 
confirmed the presence of DM-resistant CLIP, as well as known T1D-associated 
autoantigenic peptides specifically binding to T1D-susceptible DQ molecules. 
Fluorescence polarization (FP) assays with purified recombinant soluble DQ proteins 
demonstrated that DQ8-CLIP is partially sensitive to DM, but with an apparent reduction 
in catalytic potency. DM sensitivity was enhanced in mutant DQ8 molecules with 
disruption of hydrogen bonds that stabilize the DQ8 in the DM-binding region. We 
hypothesize that a relative DM editing resistance of T1D-associated DQ2, DQ8, and 
DQ2/8 trans-dimer molecules may contribute to the pathogenesis of T1D, by affecting 
the selection and activation of autoreactive CD4+ T cells. 
 
Results 
Relative resistance to DM editing of T1D-susceptible cis- and 
trans-DQ molecule 
To investigate the DM editing sensitivity of the T1D-susceptible DQ2, DQ8, and 
DQ2/8 molecules, we expressed each of the four DQ molecules or the controls, T1D-
protective DQ6 or T1D-neutral DQ1 molecules, in the 293T cells, which do not express 
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endogenous Ii or MHCII. All six DQ molecules were efficiently expressed at the cell 
surface in the absence or presence of Ii, confirming that the two trans-dimerss potentially 
expressed in DQ2/8 heterozygotes, DQ2-8 and DQ8-2, are efficiently assembled and 
transported to the cell surface [28, 29] (Figure 2.1). Cell surface CLIP levels, measured 
by flow cytometry with CerCLIP.1, a mAb specifically recognizing CLIP1 peptides with 
N-terminal extensions (Figure 2.S1), were high for each of the T1D-susceptible DQ 
molecules and the DQ6 control on cells coexpressing Ii in the absence of DM, 
demonstrating functional association with Ii, proteolytic processing to generate CLIP, and 
inefficient release of CLIP in the absence of DM (Figure 2.1). Coexpression of DM 
resulted in a complete loss of cell surface CLIP on cells expressing the control molecule 
DQ6. By contrast, DQ2-CLIP complexes were relatively resistant to DM editing, 
confirming previous reports demonstrating that DQ2 is a poor substrate for DM [22, 24]. 
Strikingly, the three other T1D-susceptible DQ molecules (DQ8, DQ2-8, and DQ8-2) 
were also observed to retain high levels of cell surface CLIP in the presence of DM 
(Figure 2.1, Figure 2.S2E). The cell lines used in these experiments expressed similar 
levels of DQ, Ii, and DM (Figure 2.1, Figure 2.S2D). Interestingly, there is no detectable 
CLIP peptide presented by DQ1 even in the absence of DM (Figure 2.1A). A hierarchy in 
DM sensitivity was observed for these molecules, with DQ8 being the least sensitive, 
followed by DQ2-8, DQ2, and DQ8-2. However, all of the four T1D-susceptible DQ 
molecules were relatively resistant to DM editing of CLIP as compared with DQ6. 
Although 293T cells have been used in MHC class II antigen presentation studies [30], 
they are not professional antigen presenting cells (APC). To explore the generality of the 
results with 293T cells, we performed additional experiments with T2 lymphoblastoid 
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cells. The T2 cell line, a hybrid human B cell line with endogenous Ii expression but with 
the deletion of entire MHC class II region in the genome [31, 32], has been used 
extensively as a model professional APC. We expressed the six different DQ alleles in T2 
cells in the absence or presence of HLA-DM and determined the effectiveness of DM in 
editing CLIP by flow cytometry. The results were consistent with those obtained with 
293T cells (Figure 2.S3). 
 
Direct analysis of DQ-bound CLIP and T1D-associated  
autoantigen-derived peptides  
We next sought to confirm DM-resistant retention of CLIP by the four T1D-
associated DQ molecules by direct identification of peptides eluted from DQ molecules. 
Peptides were eluted from affinity-purified DQ molecules isolated from 293T cells 
coexpressing Ii with or without DM, and samples were analyzed by HPLC-MS/MS. 
Consistent with the findings from flow cytometry, CLIP peptides were prominently 
presented by all DQ alleles in cells expressing Ii but not DM (Figure 2.2, left). A large 
number of nested peptides ranging from 9 to 24 amino acids in length were identified that 
contained the classical CLIP1 core sequence (boxed) [33] as well as the alternative 
CLIP2 register (gray highlight). Consistent with the flow cytometry results, CLIP was not 
detected in peptide eluates from cells expressing DQ6+Ii+DM, indicating efficient DM 
editing on DQ6-CLIP complexes (Figure 2.2, right). By contrast, CLIP1 was detected in 
peptide samples from cells coexpressing DM and each of the T1D-susceptible DQ 
molecules, supporting the conclusion that CLIP1 bound to these alleles is resistant to DM 
editing. Strikingly, Ii-derived CLIP peptides, including both CLIP1 and CLIP2 registers, 
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were also detected in peptide samples coexpressing DQ1 and Ii, but not in samples 
coexpressing DM, indicating that DQ1 molecules do present CLIP peptides and DM 
efficiently mediates the editing of DQ1-CLIP complexes (Figure 2.2). However, most of 
the CLIP1 peptides presented by DQ1 molecules lack the N-terminal extensions, the 
epitope recognized by the CerCLIP.1 mAb [34], which is consistent with the flow 
cytometry observations and CerCLIP.1 mAb specificity (Figure 2.1A, Figure 2.S1). 
CLIP2 peptides were highly represented in peptide samples eluted from DQ2 [35-37]. It 
is not known if DQ2-CLIP2 is generated by an alternative association of Ii with DQ2 in 
the endoplasmic reticulum (ER), or from rebinding of Ii fragments in this register in 
endosomal compartments [24]. Our results demonstrate that CLIP2 associates with DQ 
molecules other than DQ2, including the T1D-protective DQ6 and T1D-neutral DQ1 
molecules. It is also interesting to note that CLIP2 peptides were also present in samples 
from cells expressing DQ2+Ii+DM, consistent with prior findings indicating the CLIP2 
register has a relatively high affinity for DQ2 [35-37].  
Previous reports (http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-
24733/) indicate that 293T cells express variable levels of some T1D-associated 
autoantigens, including heat shock protein 60 (HSP60), zinc transporter 8 (ZnT8), and 
insulinoma antigen-2 (IA-2) [38]. Interestingly, we identified peptides from these 
autoantigens in samples eluted from T1D-susceptible DQ molecules but not from T1D-
neutral DQ1 or T1D-protective DQ6 (Supporting Information Table 2S.1). Strikingly, a 
peptide from ZnT8 was identified in samples from all four T1D-susceptible DQ 
molecules.  Peptides with overlapping sequence from HSP60, were detected in DQ8, 
DQ2-8, and DQ8-2 samples. These peptide sequences, as well as an additional HSP60 
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peptide eluted from DQ2-8 and three IA-2 peptide sequences eluted from DQ8, DQ2-8, 
and DQ8-2 samples have been previously reported as positive stimulators in autoreactive 
CD4+ T cell activation assays (Table 2.1) [39-52]. We also confirmed that the ZnT8 
peptide binds T1D-susceptible DQ molecules with relatively higher binding affinity than 
the pan-DQ binding peptide, CLIP1 (Figure 2.3). These results confirm that functionally 
relevant autoantigenic peptides can be identified by HPLC-MS/MS analysis of peptide 
isolated from cells expressing autoantigen proteins, although the physiologic processing 
mechanisms for presentation of these epitopes in professional APC might be different, 
and they raise the possibility that key self-peptide epitopes can be presented by multiple 
different T1D-susceptible DQ molecules. 
 
DM catalytic potency in CLIP dissociation from soluble DQ6,  
DQ2, and DQ8  
To further characterize the biochemical properties of these DQ molecules, soluble 
DQ (sDQ) proteins, sDQ6, sDQ2, and sDQ8 were generated. The sDQ-peptide 
complexes were preloaded with labeled CLIP peptide (488CLIP), and peptide dissociation 
rates were measured as a function of DM concentration (Figure 2.4). DM efficiently 
catalyzed the dissociation of CLIP from the control DQ6 protein. Peptide dissociation 
rates increased with increasing DM concentration. Note that rates appeared to saturate 
with increasing DM concentration. This might reflect a relatively high affinity in DM 
binding to DQ6-CLIP complexes. By contrast, DQ2-CLIP complexes were resistant to 
DM activity, showing little enhancement in dissociation with high DM concentrations. 
An intermediate level of DM potency was observed with DQ8-CLIP complexes. A clear 
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catalytic effect is evident with DQ8, but the rate enhancement was less than that observed 
with DQ6 as judged by the initial slope of rate versus DM concentration. Furthermore, 
less rate saturation was observed, consistent with the idea that DM may have a lower 
affinity for DQ8-CLIP as compared with DQ6-CLIP. This is illustrated in normalized 
plots of fold-enhancement in rates versus DM concentration (Figure 2.4B, right). Thus, 
experiments with purified recombinant proteins demonstrate a striking resistance of DQ2 
to DM-mediated CLIP editing and an intermediate DM-resistance phenotype for DQ8. 
 
Contribution of unique hydrogen bonds in DQ8 to its  
DM-editing resistance  
It has previously been demonstrated that a natural α53 deletion in the DQ2 α 
chain contributes to the resistance of this protein to DM catalytic activity. Introduction of 
Gly at position 53 in DQ2 restored DM sensitivity [22]. The natural deletion in DQ2α is 
positioned in the DM contact interface [21] and thus it may reduce the affinity of the DM 
interaction with DQ2 or alter the structure of the interface such that catalytic potency is 
reduced.  This would also provide a structural explanation for the DM resistant phenotype 
of the DQ2-8 trans-dimer, which shares the α chain with DQ2. However, the DQ8 α 
chain does not have this natural deletion and the structural basis of DQ8 and DQ8-2 
trans-dimer for a relative resistance to DM editing remained to be explored. 
Comparison of the crystal structures of different DQ molecules, as well as DR1 
bound to different peptides and the DM-DR1 cocrystal structure, demonstrates 
conformational differences in the helix-β-sheet region near the P1 pocket of the peptide 
binding groove, the DM interaction site [23]. Compared with the other DQ molecules, 
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there are multiple positively charged arginine residues in the 310-helix region of DQ8 α 
chain (Figure 2.5A). Notably, three extra hydrogen bonds (H-bonds) are present between 
the two helixes near the P1 pocket of DQ8 peptide binding groove (Figure 2.5A, B), as 
well as one H-bond in DQ8-2, but none in DQ1, DQ6, DQ2, or DQ2-8 [23]. To test 
whether these H-bonds contribute to the relative resistance of DQ8 to DM editing, we 
replaced the residues in the DQ8 β chain that participate in these H-bonds with the amino 
acids present in DQ6, with the goal of disrupting the extra H-bond(s) formed with the 310-
helix of DQ8α. The mutant DQ8 proteins were expressed with Ii in the absence or 
presence of DM in 293T cells (Figure 2.5C). The βT89G mutation, intended to disrupt 
one H-bond between αR52 and βT89, resulted in little change in DM sensitivity, such 
that CLIP levels remained high in the presence of DM. However, disruption of two H-
bonds through the βE86A substitution resulted in restoration of a substantial increase in 
sensitivity to DM editing, as determined by comparing CLIP levels with and without 
coexpression of DM (Figure 2.5C, D). These findings support the idea that the additional 
H-bonds between the α and β chain helices in DQ8 may contribute to a phenotype of 
relative resistance to DM editing, possibly by stabilizing the region of MHCII that 
undergoes a marked conformation transition when bound to DM.   
 
Discussion 
Collectively, our findings indicate that the four T1D-susceptible DQ molecules, 
DQ2, DQ8, and the trans-dimerss expressed in DQ2/8 heterozygotes, share a distinct 
property of being relatively resistant to DM-mediated editing of CLIP, compared with the 
T1D-protective DQ6 or T1D-neutral DQ1 molecules that have the classical DM-sensitive 
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phenotype. The most direct evidence for this conclusion was obtained by analyzing 
surface CLIP levels on cells with or without coexpression of DM. We observed little or 
no reduction in CLIP levels on 293T cells coexpressing DM with DQ8 or DQ2-8, 
indicating a significant DM editing resistance of CLIP peptides. The phenotype was less 
striking for the DQ2 and DQ8-2 trans-dimer (Figure 2.1). Similar results were obtained 
with T2 lymphoblastoid cells; however, DQ2 and DQ2-8 were less sensitive to DM than 
DQ8 in these cells. 
The α chain of DQ2 (DQA1*0501) contains a deletion of residue 53. Insertion of 
Gly at this position was shown to restore sensitivity to DM as judged by a marked 
increase in DM-mediated rate enhancement in the dissociation of a DQ2 binding peptide 
[22]. Given the location of α53 in the DM contact interface [21], it is tempting to 
consider the possibility that the natural α53 deletion in DQ2 (and the DQ2-8 trans-dimer) 
confers a general resistance to DM-mediated peptide exchange, reducing the impact of 
DM editing on the peptide repertoire presented by these molecules. However, additional 
structural elements may also contribute to the DM editing sensitivity. The 
DQA1*0501/DQB1*0301 DQ7 allele shares DQA1*0501 with DQ2, yet it is not 
associated with T1D. Other DQA alleles represented in human populations have a natural 
deletion at α53, including DQA1*0201 and DQA1*04. Further work will be needed to 
determine the DM sensitivity of the proteins generated from these alleles and the 
structural features that affect DM catalytic efficiency. There is an inverse relationship 
between the intrinsic stability of peptide complexes and sensitivity to DM-catalyzed 
peptide dissociation, such that less stable complexes are selectively edited, and more 
stable complexes survive for recognition by CD4+ T cells [10, 53, 54]. Reduction in DM 
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editing might broaden the array of self-peptide complexes available to activate 
autoreactive T cells, and unstable complexes may be more susceptible to alternative 
peptide loading pathways for exogenous autoantigenic peptides [55].  
In experiments with sDQ molecules, high concentrations of DM were observed to 
have little effect on the rate of dissociation of CLIP from sDQ2, whereas DM was clearly 
able to enhance CLIP dissociation from DQ8 in a dose-dependent manner. DM catalytic 
potency was intermediate between DQ2 and the DM-sensitive DQ6 control. The stability 
of sDQ8-CLIP complexes was observed to be considerably greater than that of sDQ6-
CLIP, with intrinsic half-lives of 58 h and 7 h, respectively. The increased stability of 
sDQ8-CLIP might explain the relative resistance to DM. While DQ8 does not have the 
α53 deletion found in DQ2, it does have three H-bonds, not present in DQ2, DQ2-8, 
DQ1, or DQ6 molecules. The H-bonds connect the helices of the α and β chains near the 
DM contact site [23]. Disruption of two H-bonds through a βE86A substitution was 
observed to partially restore sensitivity to DM in cells expressing the substituted DQ 
protein. It is possible that the mutation reduces the intrinsic stability of DQ8 molecule as 
well as the complex of DQ8-CLIP, as a potential mechanism for enhancing DM 
sensitivity. Alternatively, the additional H-bonds in DQ8 might serve to stabilize the DM-
binding region of DQ8, making it more difficult for the molecule to undergo the 
conformational rearrangement required for interaction with DM [21]. It is interesting to 
note that the DQ8-2 trans-dimer has one additional H-bond [23] that could potentially 
stabilize the conformation of the peptide-binding groove and contribute to the partial 
DM-resistant phenotype observed in cells expressing this mixed haplotype DQ molecule.  
HPLC-MS/MS analysis confirmed that Ii-derived peptides lacking the core CLIP1 
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sequence and containing the alternative CLIP2 binding register were highly represented 
in samples from cells expressing DQ2+Ii. The CLIP2 loading mechanism is unknown, 
reflecting either an alternative mode of assembly of Ii with DQ2 or an exchange 
mechanism in which CLIP1 is replaced by CLIP2 [24]. CLIP2 peptides were also 
prominently represented in samples from cells expressing DQ1, DQ6, DQ8, or the DQ8/2 
trans-dimers in the absence of DM expression. While the biological significance of 
CLIP2 is unknown, it is clear that CLIP2 is not uniquely associated with DQ2 or T1D-
associated DQ molecules. The detection of CLIP peptides in DQ1 peptide samples by 
HPLC-MS/MS, but not by CerCLIP.1 mAb surface staining, reflects the specificity of the 
CerCLIP.1 mAb, for only long CLIP1 peptides with N-terminal sequence extensions. The 
peptide elution data confirm that DQ1-CLIP is sensitive to DM editing. However, the 
mechanism responsible for selective loading of DQ1 with short CLIP peptides remains to 
be investigated, possibly reflecting an increased sensitivity to proteolytic trimming.  
A number of peptides from well known T1D-associated autoantigens were 
identified in the HPLC-MS/MS experiments with samples from T1D-susceptible DQ 
molecules. The 293T human embryonic kidney cell line fortuitously expresses some of 
the proteins relevant in T1D pathogenesis. Further work will be needed to determine 
whether specific peptides are dependent on DM for presentation, or sensitive to DM 
editing such that DM-independent presentation mechanisms would be required for T cell 
recognition. It was interesting to observe that several peptides were identified with 
multiple different T1D-susceptible DQ molecules, but not with DQ1 or DQ6. Strikingly, 
a ZnT8 peptide was eluted from cells expressing each of the T1D-susceptible DQ alleles. 
This raises the question of whether presentation of selected peptides by the multiple 
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different DQ molecules expressed on the cells in DQ8/2 heterozygotes might play a role 
in inducing cross-reacting autoreactive T cell responses in these individuals [56]. It was 
also interesting that most of the peptide sequences identified from T1D autoantigens had 
previously been defined as epitopes for autoreactive CD4+ T cell responses in T1D. This 
provides some level of validation that mass spectrometric analysis of MHCII-associated 
peptides may be useful in identifying candidate autoantigenic epitopes. 
Overall, we conclude that the four T1D-susceptible DQ alleles have in common a 
shared resistance to DM-mediated editing of CLIP. Different structural elements appear 
to be responsible for this phenotype in DQ2, DQ8, and the DQ2/8 trans-dimers. Cell 
surface CLIP levels have been reported to be elevated in the peripheral blood of people 
with T1D [57]. It is possible that high levels of CLIP in the thymus might result in less 
efficient negative selection of a population of self-reactive T cells with the potential to 
participate in initiating or propagating immune responses to islet antigens. Alternatively, 
reduced susceptibility to DM editing function could potentially facilitate peripheral 
presentation of self-peptides loaded under inflammatory conditions through DM-
independent mechanisms. Unanue and colleagues have demonstrated that DM-
independent loading of free peptides can result in the formation of peptide-MHCII 
complexes with alterative binding registers [58]. These alternatively-generated peptide 
complexes can activate a population of unconventional “type B” T cells that are not 
eliminated through conventional mechanisms that maintain self tolerance [55]. While 
there is little doubt that the impact of MHCII polymorphism on CD4+ T cell repertoire 
selection and epitope specificity must play a major role in determining genetic 
susceptibility to specific autoimmune diseases, allelic differences that impact the peptide 
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loading pathway may also be important.  
 
Materials and Methods 
Expression of DQ, Ii and DM molecules and purification of full  
length and soluble DQ in 293T cells 
 Constructs encoding the full length α and β chains of DQ1, DQ2, DQ6, or DQ8 
were fused with the T2A sequence [59] and cloned into pWPI vector (Addgene). Human 
Ii cDNA was cloned into another pWPI vector. The DM construct was cloned from 
MigR1-DM [60] and inserted behind the IRES site within lentiviral HIV\CS\Ub-ChIT 
(ChIT) vector provided by Dr. Vicente Planelles (University of Utah), which contains an 
mCherry gene driven by a human ubiquitin promoter (Figure 2.S2A, B). High-titer 
lentiviral supernatants were generated by transfection of 293T cells (ATCC), a human 
embryonic kidney cell line having no endogenous expression of Ii, DM, or DQ, with 
pWPI-DQ, pWPI-Ii, or ChIT-DM construct, as previously described [61]. The 293T 
transductants stably expressing DQ (DQ only) or DQ and Ii (DQ+Ii) were sorted for GFP 
and DQ expression with a FACSAriaTM cell sorter (BD Biosciences). DQ+Ii cells were 
further transduced with ChIT-DM lentivirus and sorted for GFP, DQ, and mCherry 
expression to obtain DQ+Ii+DM cells (Figure 2.S2C). Full length DQ (fDQ) was purified 
from DQ+Ii 293T cells by SPVL3 affinity column [53]. Full length DM (fDM) was 
purified as previously described [53]. Soluble DQ proteins were generated from pWPI-
sDQ lentiviral transduced 293T cells using the construct as previously described [62].  
The culture media were precleared and incubated with His-Tag Purification Resin 
(Roche), and the eluates were further purified by SPVL3 affinity column. Purified sDQ 
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were overnight cleaved with immobilized thrombin (EMD Millipore) in PBS at room 
temperature to facilitate the release of endogenous CLIP peptide. Soluble DM was 
purified as previously described [60]. 
 
Abs and flow cytometry   
The following mAbs, DM-PE (clone Map.DM1; BD Pharmingen), CLIP-PerCP-
Cy5.5 (clone CerCLIP.1; Santa Cruz Biotechnology) and isotype-matched negative 
controls, were used in cell staining. To staining DQ, purified mAb to DQ (clone SPVL3, 
ATCC) was labeled with Biotinamidohexanoic acid N-hydroxysuccinimide ester (Sigma) 
then accordingly stained by streptavidin-APC or -PE-Cy7 (Invitrogen). Purified mAb to 
Ii (clone PIN-1), provided by Dr. Peter Cresswell (Yale), was conjugated with Alexa 
Fluor® 647 (Invitrogen). Intracellular staining was performed with the Cytofix/Cytoperm 
kit (BD Biosciences). Stained cells were analyzed by LSRFortessaTM flow cytometer (BD 
Biosciences). The data were analyzed using FlowJo software (Tree Star). Based on GFP, 
mCherry and surface DQ expression, cells were sorted with FACSAriaTM cell sorter (BD 
Biosciences) at the core facility of University of Utah. The sDQ 293T transductants were 
sorted for high GFP expression, and sDQ secretion in culture media was measured by 
immunoassay [63], using SPVL3 and biotin-IVA12 mAbs.  
 
Peptide elution and HPLC-MS/MS sequence analysis  
To elute peptides bound to each DQ molecules, ~1x109 of each DQ+Ii or 
DQ+Ii+DM transductant 293T cells were lysed and the DQ molecules were captured by 
anti-DQ mAb (SPVL3) immobilized with protein A beads. Bound peptides were eluted 
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and further separated by HPLC for HPLC-MS/MS analysis as previously described [64].   
 
Peptide competition and fluorescence polarization assay  
N-acetylated CLIP (80-103, KLPKPPKPVSKMRMATPLLMQALC), in which 
the last residue was substituted by cysteine for labeling, was commercially synthesized 
(CelTek Pepitdes) and labeled with BMCC-biotin (Pierce), designated as bCLIP. The N-
acetylated peptide CLIP (VSKMRMATPLLMQ) was labeled on lysine (underlined) with 
Alexa Fluor 488 (Molecular Probes) as previously described, designated as 488CLIP [60]. 
The peptides, CLIP1 (LPKPPKPVSKMRMATPLLMQA), CLIPc 
(PSSGLGVTKQDLGPVPM) and ZnT8(126) (KPPSKRLTFGWHRAEILGAL), were 
used as competitor peptides in competition assays. Briefly, 100 nM fDQ, 1 µM bCLIP, 
200 nM fDM, and the competitor peptide (0, 2, 20 or 200 µM) were incubated at 37oC for 
3 h in 100 mM citrate-phosphate buffer (pH 5.0) with 0.2% NP-40. Sample was loaded 
into 96-well plate coated with SPVL3 mAb, and detected by immunoassay [63]. The 
relative loading of bCLIP to specific DQ molecules was normalized to the reaction 
without competitor peptides. Thrombin-cleaved sDQ was preloaded with extra 488CLIP 
(1:5 molar ratio) in FP buffer (10 mM citrate-phosphate buffer, pH 5.0, 150 mM NaCl, 
0.05% Tween 20), at 37oC for 3 h (for sDQ6) or overnight (for sDQ2) with 100 nM sDM, 
or at 37oC overnight without sDM (for sDQ8), due to the different DM sensitivity. 
Unbound 488CLIP peptide was removed by buffer exchange with 30-kD cut-off spin 
column (Millipore). In FP assay, 50 nM sDQ-488CLIP complex, sDM (0 to 2000 nM), and 
100 µM competitor peptide were incubated in FP buffer and measured at 37oC with a 
Tecan Infinite F200 plate reader. FP value was normalized by the background FP signal 
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of free 488CLIP peptides, and the data were processed with Prism 5.0 (GraphPad 




1 Pociot, F., Akolkar, B., Concannon, P., Erlich, H. A., Julier, C., Morahan, G., 
Nierras, C. R. et al., Genetics of type 1 diabetes: what's next? Diabetes 2010. 59: 
1561-1571. 
2 Gorodezky, C., Alaez, C., Murguia, A., Rodriguez, A., Balladares, S., Vazquez, 
M., Flores, H. and Robles, C., HLA and autoimmune diseases: Type 1 diabetes 
(T1D) as an example. Autoimmun. Rev. 2006. 5: 187-194. 
3 Cifuentes, R. A., Rojas-Villarraga, A. and Anaya, J. M., Human leukocyte antigen 
class II and type 1 diabetes in Latin America: a combined meta-analysis of 
association and family-based studies. Hum. Immunol. 2011. 72: 581-586. 
4 Rojas-Villarraga, A., Botello-Corzo, D. and Anaya, J. M., HLA-Class II in Latin 
American patients with type 1 diabetes. Autoimmun. Rev. 2010. 9: 666-673. 
5 van Autreve, J. E., Weets, I., Gulbis, B., Vertongen, F., Gorus, F. K., van der 
Auwera, B. J. and Belgian Diabetes, R., The rare HLA-DQA1*03-DQB1*02 
haplotype confers susceptibility to type 1 diabetes in whites and is preferentially 
associated with early clinical disease onset in male subjects. Hum. Immunol. 2004. 
65: 729-736. 
6 Aly, T. A., Ide, A., Jahromi, M. M., Barker, J. M., Fernando, M. S., Babu, S. R., 
Yu, L. et al., Extreme genetic risk for type 1A diabetes. Proc. Natl. Acad. Sci. USA 
2006. 103: 14074-14079. 
7 Erlich, H., Valdes, A. M., Noble, J., Carlson, J. A., Varney, M., Concannon, P., 
Mychaleckyj, J. C. et al., HLA DR-DQ haplotypes and genotypes and type 1 
diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes 
2008. 57: 1084-1092. 
8 Pociot, F. and McDermott, M. F., Genetics of type 1 diabetes mellitus. Genes. 
Immun. 2002. 3: 235-249. 
9 Neefjes, J., Jongsma, M. L., Paul, P. and Bakke, O., Towards a systems 
understanding of MHC class I and MHC class II antigen presentation. Nat. Rev. 
Immunol. 2011. 11: 823-836. 
10 Jensen, P. E., Recent advances in antigen processing and presentation. Nat. Immunol. 
2007. 8: 1041-1048. 
  
27 
11 Sant, A. J., Chaves, F. A., Leddon, S. A. and Tung, J., The control of the 
specificity of CD4 T cell responses: thresholds, breakpoints, and ceilings. Front 
Immunol. 2013. 4: 340. 
12 Fairchild, P. J., Wildgoose, R., Atherton, E., Webb, S. and Wraith, D. C., An 
autoantigenic T cell epitope forms unstable complexes with class II MHC: a novel 
route for escape from tolerance induction. Int. Immunol. 1993. 5: 1151-1158. 
13 Geluk, A., van Meijgaarden, K. E., Schloot, N. C., Drijfhout, J. W., Ottenhoff, T. 
H. and Roep, B. O., HLA-DR binding analysis of peptides from islet antigens in 
IDDM. Diabetes 1998. 47: 1594-1601. 
14 Gross, D. A., Graff-Dubois, S., Opolon, P., Cornet, S., Alves, P., Bennaceur-
Griscelli, A., Faure, O. et al., High vaccination efficiency of low-affinity epitopes in 
antitumor immunotherapy. J. Clin. Invest 2004. 113: 425-433. 
15 Liu, G. Y., Fairchild, P. J., Smith, R. M., Prowle, J. R., Kioussis, D. and Wraith, 
D. C., Low avidity recognition of self-antigen by T cells permits escape from central 
tolerance. Immunity 1995. 3: 407-415. 
16 McNeil, L. K. and Evavold, B. D., Dissociation of peripheral T cell responses from 
thymocyte negative selection by weak agonists supports a spare receptor model of T 
cell activation. Proc. Natl. Acad. Sci. USA 2002. 99: 4520-4525. 
17 Stadinski, B. D., Zhang, L., Crawford, F., Marrack, P., Eisenbarth, G. S. and 
Kappler, J. W., Diabetogenic T cells recognize insulin bound to IAg7 in an 
unexpected, weakly binding register. Proc. Natl. Acad. Sci. USA 2010. 107: 10978-
10983. 
18 Crawford, F., Stadinski, B., Jin, N., Michels, A., Nakayama, M., Pratt, P., 
Marrack, P. et al., Specificity and detection of insulin-reactive CD4+ T cells in type 
1 diabetes in the nonobese diabetic (NOD) mouse. Proc. Natl. Acad. Sci. USA 2011. 
108: 16729-16734. 
19 Levisetti, M. G., Lewis, D. M., Suri, A. and Unanue, E. R., Weak proinsulin 
peptide-major histocompatibility complexes are targeted in autoimmune diabetes in 
mice. Diabetes 2008. 57: 1852-1860. 
20 Yang, J., Chow, I. T., Sosinowski, T., Torres-Chinn, N., Greenbaum, C. J., 
James, E. A., Kappler, J. W. et al., Autoreactive T cells specific for insulin B:11-23 
recognize a low-affinity peptide register in human subjects with autoimmune 
diabetes. Proc. Natl. Acad. Sci. USA 2014. 111: 14840-14845. 
21 Pos, W., Sethi, D. K., Call, M. J., Schulze, M. S., Anders, A. K., Pyrdol, J. and 
Wucherpfennig, K. W., Crystal structure of the HLA-DM-HLA-DR1 complex 
defines mechanisms for rapid peptide selection. Cell 2012. 151: 1557-1568. 
22 Hou, T., Macmillan, H., Chen, Z., Keech, C. L., Jin, X., Sidney, J., Strohman, M. 
  
28 
et al., An insertion mutant in DQA1*0501 restores susceptibility to HLA-DM: 
implications for disease associations. J. Immunol. 2011. 187: 2442-2452. 
23 Zhou, Z. and Jensen, P. E., Structural Characteristics of HLA-DQ that May Impact 
DM Editing and Susceptibility to Type-1 Diabetes. Front Immunol. 2013. 4: 262. 
24 Fallang, L. E., Roh, S., Holm, A., Bergseng, E., Yoon, T., Fleckenstein, B., 
Bandyopadhyay, A. et al., Complexes of two cohorts of CLIP peptides and HLA-
DQ2 of the autoimmune DR3-DQ2 haplotype are poor substrates for HLA-DM. J. 
Immunol. 2008. 181: 5451-5461. 
25 Lundin, K. E., Gjertsen, H. A., Scott, H., Sollid, L. M. and Thorsby, E., Function 
of DQ2 and DQ8 as HLA susceptibility molecules in celiac disease. Hum. Immunol. 
1994. 41: 24-27. 
26 Busch, R., De Riva, A., Hadjinicolaou, A. V., Jiang, W., Hou, T. and Mellins, E. 
D., On the perils of poor editing: regulation of peptide loading by HLA-DQ and H2-A 
molecules associated with celiac disease and type 1 diabetes. Expert. Rev. Mol. Med. 
2012. 14: e15. 
27 Morgan, M. A., Muller, P. S., Mould, A., Newland, S. A., Nichols, J., Robertson, 
E. J., Cooke, A. and Bikoff, E. K., The nonconventional MHC class II molecule DM 
governs diabetes susceptibility in NOD mice. PLoS One 2013. 8: e56738. 
28 van Lummel, M., van Veelen, P. A., Zaldumbide, A., de Ru, A., Janssen, G. M., 
Moustakas, A. K., Papadopoulos, G. K. et al., Type 1 diabetes-associated HLA-
DQ8 transdimer accommodates a unique peptide repertoire. J. Biol. Chem. 2012. 287: 
9514-9524. 
29 Tollefsen, S., Hotta, K., Chen, X., Simonsen, B., Swaminathan, K., Mathews, II, 
Sollid, L. M. and Kim, C. Y., Structural and functional studies of trans-encoded 
HLA-DQ2.3 (DQA1*03:01/DQB1*02:01) protein molecule. J. Biol. Chem. 2012. 
287: 13611-13619. 
30 Testa, J. S., Apcher, G. S., Comber, J. D. and Eisenlohr, L. C., Exosome-driven 
antigen transfer for MHC class II presentation facilitated by the receptor binding 
activity of influenza hemagglutinin. J. Immunol. 2010. 185: 6608-6616. 
31 Kovats, S., Whiteley, P. E., Concannon, P., Rudensky, A. Y. and Blum, J. S., 
Presentation of abundant endogenous class II DR-restricted antigens by DM-negative 
B cell lines. Eur. J. Immunol. 1997. 27: 1014-1021. 
32 Hosken, N. A. and Bevan, M. J., Defective presentation of endogenous antigen by a 
cell line expressing class I molecules. Science 1990. 248: 367-370. 
33 Ghosh, P., Amaya, M., Mellins, E. and Wiley, D. C., The structure of an 




34 Denzin, L. K., Robbins, N. F., Carboy-Newcomb, C. and Cresswell, P., Assembly 
and intracellular transport of HLA-DM and correction of the class II antigen-
processing defect in T2 cells. Immunity 1994. 1: 595-606. 
35 Wiesner, M., Stepniak, D., de Ru, A. H., Moustakis, A. K., Drijfhout, J. W., 
Papadopoulos, G. K., van Veelen, P. A. and Koning, F., Dominance of an 
alternative CLIP sequence in the celiac disease associated HLA-DQ2 molecule. 
Immunogenetics 2008. 60: 551-555. 
36 van de Wal, Y., Kooy, Y. M., Drijfhout, J. W., Amons, R. and Koning, F., Peptide 
binding characteristics of the coeliac disease-associated DQ(alpha1*0501, 
beta1*0201) molecule. Immunogenetics 1996. 44: 246-253. 
37 Vartdal, F., Johansen, B. H., Friede, T., Thorpe, C. J., Stevanovic, S., Eriksen, J. 
E., Sletten, K. et al., The peptide binding motif of the disease associated HLA-DQ 
(alpha 1* 0501, beta 1* 0201) molecule. Eur. J. Immunol. 1996. 26: 2764-2772. 
38 Roep, B. O. and Peakman, M., Antigen targets of type 1 diabetes autoimmunity. 
Cold Spring Harb. Perspect. Med. 2012. 2: a007781. 
39 Abulafia-Lapid, R., Elias, D., Raz, I., Keren-Zur, Y., Atlan, H. and Cohen, I. R., 
T cell proliferative responses of type 1 diabetes patients and healthy individuals to 
human hsp60 and its peptides. J. Autoimmun. 1999. 12: 121-129. 
40 Chujo, D., Foucat, E., Nguyen, T. S., Chaussabel, D., Banchereau, J. and Ueno, 
H., ZnT8-Specific CD4+ T cells display distinct cytokine expression profiles between 
type 1 diabetes patients and healthy adults. PLoS One 2013. 8: e55595. 
41 Dang, M., Rockell, J., Wagner, R., Wenzlau, J. M., Yu, L., Hutton, J. C., 
Gottlieb, P. A. and Davidson, H. W., Human type 1 diabetes is associated with T 
cell autoimmunity to zinc transporter 8. J. Immunol. 2011. 186: 6056-6063. 
42 Dosch, H., Cheung, R. K., Karges, W., Pietropaolo, M. and Becker, D. J., 
Persistent T cell anergy in human type 1 diabetes. J. Immunol. 1999. 163: 6933-6940. 
43 Honeyman, M. C., Stone, N. L. and Harrison, L. C., T-cell epitopes in type 1 
diabetes autoantigen tyrosine phosphatase IA-2: potential for mimicry with rotavirus 
and other environmental agents. Mol. Med. 1998. 4: 231-239. 
44 Huurman, V. A., van der Meide, P. E., Duinkerken, G., Willemen, S., Cohen, I. 
R., Elias, D. and Roep, B. O., Immunological efficacy of heat shock protein 60 
peptide DiaPep277 therapy in clinical type I diabetes. Clin. Exp. Immunol. 2008. 152: 
488-497. 
45 Jonson, C. O., Lernmark, A., Ludvigsson, J., Rutledge, E. A., Hinkkanen, A. and 
Faresjo, M., The importance of CTLA-4 polymorphism and human leukocyte 
antigen genotype for the induction of diabetes-associated cytokine response in healthy 
school children. Pediatr. Diabetes 2007. 8: 185-192. 
  
30 
46 Kudva, Y. C., Deng, Y. J., Govindarajan, R., Abraham, R. S., Marietta, E. V., 
Notkins, A. L. and David, C. S., HLA-DQ8 transgenic and NOD mice recognize 
different epitopes within the cytoplasmic region of the tyrosine phosphatase-like 
molecule, IA-2. Hum. Immunol. 2001. 62: 1099-1105. 
47 Peakman, M., Stevens, E. J., Lohmann, T., Narendran, P., Dromey, J., 
Alexander, A., Tomlinson, A. J. et al., Naturally processed and presented epitopes 
of the islet cell autoantigen IA-2 eluted from HLA-DR4. J. Clin. Invest 1999. 104: 
1449-1457. 
48 Petrich de Marquesini, L. G., Fu, J., Connor, K. J., Bishop, A. J., McLintock, N. 
E., Pope, C., Wong, F. S. and Dayan, C. M., IFN-gamma and IL-10 islet-antigen-
specific T cell responses in autoantibody-negative first-degree relatives of patients 
with type 1 diabetes. Diabetologia 2010. 53: 1451-1460. 
49 Schulz, R. M., Hawa, M., Leslie, R. D., Sinigaglia, F., Passini, N., Rogge, L., 
Picard, J. K. and Londei, M., Proliferative responses to selected peptides of IA-2 in 
identical twins discordant for Type 1 diabetes. Diabetes Metab. Res. Rev. 2000. 16: 
150-156. 
50 Shpigel, E., Elias, D., Cohen, I. R. and Shoseyov, O., Production and purification of 
a recombinant human hsp60 epitope using the cellulose-binding domain in 
Escherichia coli. Protein Expr. Purif. 1998. 14: 185-191. 
51 Szebeni, A., Schloot, N., Kecskemeti, V., Hosszufalusi, N., Panczel, P., 
Prohaszka, Z., Fust, G. et al., Th1 and Th2 cell responses of type 1 diabetes patients 
and healthy controls to human heat-shock protein 60 peptides AA437-460 and 
AA394-408. Inflamm Res. 2005. 54: 415-419. 
52 Vaughan, K., Peters, B., Mallone, R., von Herrath, M., Roep, B. O. and Sette, A., 
Navigating diabetes-related immune epitope data: resources and tools provided by the 
Immune Epitope Database (IEDB). Immunome. Res. 2013. 9, doi: 10.4172/1745-
7580.1000063. 
53 Weber, D. A., Evavold, B. D. and Jensen, P. E., Enhanced dissociation of HLA-
DR-bound peptides in the presence of HLA-DM. Science 1996. 274: 618-620. 
54 Belmares, M. P., Busch, R., Wucherpfennig, K. W., McConnell, H. M. and 
Mellins, E. D., Structural factors contributing to DM susceptibility of MHC class 
II/peptide complexes. J. Immunol. 2002. 169: 5109-5117. 
55 Mohan, J. F. and Unanue, E. R., Unconventional recognition of peptides by T cells 
and the implications for autoimmunity. Nat. Rev. Immunol. 2012. 12: 721-728. 
56 Kooy-Winkelaar, Y., van Lummel, M., Moustakas, A. K., Schweizer, J., Mearin, 
M. L., Mulder, C. J., Roep, B. O. et al., Gluten-specific T cells cross-react between 




57 Silva, D. G., Socha, L., Correcha, M. and Petrovsky, N., Elevated lymphocyte 
expression of CLIP is associated with type 1 diabetes and may be a useful marker of 
autoimmune susceptibility. Ann. NY Acad. Sci. 2004. 1037: 65-68. 
58 Pu, Z., Lovitch, S. B., Bikoff, E. K. and Unanue, E. R., T cells distinguish MHC-
peptide complexes formed in separate vesicles and edited by H2-DM. Immunity 2004. 
20: 467-476. 
59 Szymczak, A. L., Workman, C. J., Wang, Y., Vignali, K. M., Dilioglou, S., Vanin, 
E. F. and Vignali, D. A., Correction of multi-gene deficiency in vivo using a single 
'self-cleaving' 2A peptide-based retroviral vector. Nat. Biotechnol. 2004. 22: 589-594. 
60 Zhou, Z., Callaway, K. A., Weber, D. A. and Jensen, P. E., Cutting edge: HLA-
DM functions through a mechanism that does not require specific conserved 
hydrogen bonds in class II MHC-peptide complexes. J. Immunol. 2009. 183: 4187-
4191. 
61 Pear, W. S., Nolan, G. P., Scott, M. L. and Baltimore, D., Production of high-titer 
helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 1993. 
90: 8392-8396. 
62 Gauthier, L., Smith, K. J., Pyrdol, J., Kalandadze, A., Strominger, J. L., Wiley, 
D. C. and Wucherpfennig, K. W., Expression and crystallization of the complex of 
HLA-DR2 (DRA, DRB1*1501) and an immunodominant peptide of human myelin 
basic protein. Proc. Natl. Acad. Sci. USA 1998. 95: 11828-11833. 
63 Tompkins, S. M., Rota, P. A., Moore, J. C. and Jensen, P. E., A europium 
fluoroimmunoassay for measuring binding of antigen to class II MHC glycoproteins. 
J. Immunol. Methods 1993. 163: 209-216. 
64 Escobar, H., Reyes-Vargas, E., Jensen, P. E., Delgado, J. C. and Crockett, D. K., 
Utility of characteristic QTOF MS/MS fragmentation for MHC class I peptides. J. 






Figure 2.1. DM editing sensitivity of Ii-derived CLIP peptides in T1D-neutral DQ1, -
protective DQ6 or -susceptible DQ2, DQ8 and DQ2/8 trans-dimers. (A) CLIP and 
DQ molecules on 293T cells transduced with DQ only (top), DQ+Ii (middle) or 
DQ+Ii+DM (bottom) were cell surface stained with fluorescence conjugated CerCLIP.1 
and SPVL3 antibodies as described in Materials and Methods. The mean fluorescence 
intensity (MFI) is stated in the panels, and indicates cell surface expression level of CLIP 
bound to DQ. (B) Relative DM editing effects indicated by comparison of the MFI ratio 
of cell surface CLIP and DQ levels in the absence or presence of DM expression. Cells 
were surface stained for CLIP and DQ and gated on the same level of GFP and/or 
mCherry expression. Data are representative of 3 independent experiments and shown as 






Figure 2.2. Pattern of eluted unique CLIP peptides. 293T cells expressing different 
DQ molecules in the absence (left, DQ+Ii) or presence (right, DQ+Ii+DM) of DM were 
used to elute peptides bound to each DQ molecules captured by anti-DQ mAb (SPVL3) 
immobilized with protein A beads. Bound peptides were eluted and further separated by 
HPLC and  analyzed by HPLC-MS/MS. The two well-defined registers of Ii-derived 
peptides are highlighted as CLIP1 (boxed) and CLIP2 (gray). Data shown are 








Figure 2.3. Binding analysis of the ZnT8-derived ZnT8(126) peptide to purified fDQ 
molecules. Peptide competition assays were performed with purified fDQ proteins and 
bCLIP, using unlabeled peptides CLIP1, CLIPc or ZnT8(126) peptides as competitor. 
CLIPc is a control peptide derived from the C-terminus of Ii that was detected by HPLC-
MS/MS from all of the samples (DQ2, DQ2-8 and DQ8-2), except DQ8. Data shown are 








Figure 2.4. CLIP dissociation rate and DM catalytic potency measured with purified 
DQ molecules. (A) The FP measurement of CLIP dissociation and DM editing effects. 
Thrombin cleaved sDQ proteins were pre-loaded with 488CLIP peptides. Peptide 
dissociation rates were measured in the presence of different concentration of sDM and 
100 µM of unlabeled CLIP1 as competitor peptides. The control represents the sample 
without adding extra sDM or competitor peptides. (B) Peptide dissociation rates of sDQ6, 
sDQ2 and sDQ8 measured by FP assay in the presence of different concentration of DM 
(left) and the DM-catalyzed rate enhancements normalized relative to dissociation rates 
measured in the absence of DM (right).  Data are representative of 3 independent 








Figure 2.5. Impact of hydrogen bonds between the two helical regions of α and β 
chains near the P1 pocket of DQ8 molecule. (A) Top view of the two helical regions of 
DQ8 α and β chains near the P1 pocket of the peptide binding groove with bound peptide 
(PDB: 1JK8). The R52 residue in the 310-helix (purple) of the α chain forms three H-
bonds with E86 and T89 in the helix (cyan) near the P1 pocket of the β chain. DQ8 
specific residues are labeled orange. (B) A close-up view of the three H-bonds formed 
between the two helixes in DQ8. (C) Comparison of CLIP level on 293T cells transduced 
with Ii and DQ6, DQ8, or DQ8 mutants, in the absence or presence of DM expression. 
The DQ8 mutants were designed to disrupt one (βT89G) or two (βE86A) H-bonds, 
respectively. The MFI of cell surface CLIP is shown. (D) The relative DM editing effects 
indicated by comparison of the ratio of CLIP/DQ in the absence or presence of DM 
expression. Cells were surface stained for CLIP and DQ and gated on the same level of 
GFP and/or mCherry expression.  Data are representative of 3 independent experiments 


























































































































































































































































































































































































































































































































































































































Figure 2.S1. N-terminus sequence of CLIP peptides and the specificity of CerCLIP.1 
mAb. (A) Sequence alignment of Ii-derived CLIP1, CLIP1* and CLIP2 peptides for the 
identification of CerCLIP.1 mAb specificity. (B) The CerCLIP.1 mAb specificity. ELISA 
plate was coated with 100 µM or 10 µM of CLIP peptides (in 50 µL) listed in (A); then 
detected with 2 µg/ml of purified CerCLIP.1 mAb (Santa Cruz Biotech), followed by 2 
µg/ml of biotinylated goat-anti-mouse IgG mAb (SouthernBiotech), and developed with 







Figure 2.S2. The expression of Ii, DQ and DM in 293T cells. (A) The α and β chain 
gene allele information of T1D-neutral, -protective and -susceptible DQ molecules. (B) 
Diagrams of the constructs and the markers for the expression of Ii, DQ or DM in 293T 
cells. (C) Strategies of lentiviral mediated gene transduction and the markers used for the 
cell sorting. 293T cells were firstly transduced by high titer of fresh lentivirus generated 
in producer cells transfected with DQ or Ii construct. Then, the transductants were sorted 
by GFP and DQ (SPVL3) expression. To generate the DQ+Ii+DM cells, DQ+Ii cells 
were further transduced by lentivirus with DM, and sorted by GFP, mCherry and cell 
surface DQ expression. (D) Comparison of the relative expression level of GFP and 
mCherry (top panel), intracellular Ii (PIN-1, middle panel) and intracellular DM 
(Map.DM1, bottom panel) in DQ+Ii+DM cells with the negative control. The MFI 
showed in the top panel with (x, y) represents the MFI of GFP and mCherry expression 
level, respectively. The MFI showed in the middle or the bottom panel represents the 
MFI of Ii or DM expression level, respectively. (E) The MFI ratio of cell surface CLIP 
and DQ levels in the absence or presence of DM expression. Cells were surface stained 
for CLIP (CerCLIP.1) and DQ (SPVL3) and gated on the same level of GFP and/or 
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Figure 2.S3. DM editing effects of T1D-associated DQ molecules on Ii-derived CLIP 
peptides in T2 transductants. (A) Cell surface presentation of Ii-derived CLIP peptides 
and DQ molecules in T2 transductants in the absence or presence of DM expression. T2 
cells were transduced with DQ and DM, using GFP and mCherry as the marker of DQ 
and DM expression, respectively. Cells were gated on GFP+mCherry- (top panel) or 
GFP+mCherry+ (bottom panel). (B) Difference of DM editing effects between T1D-
associated and nonassociated DQ molecules. The DM editing effects are indicated by the 
ratio of surface CLIP/DQ MFI (mean fluorescence index) between the cells in the 
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PEPTIDOMIC ANALYSIS OF TYPE 1 DIABETES ASSOCIATED 
HLA-DQ MOLECULES AND THE IMPACT OF HLA-DM 




HLA-DM is critical in editing peptide repertoires presented by MHCII on antigen 
presenting cells (APC), thus influencing the selection/activation of CD4+ T cells. We 
previously reported that type 1 diabetes (T1D) associated HLA-DQ2, DQ8, and DQ2/8 
molecules are relatively resistant to DM editing of the invariant chain (Ii) derived CLIP 
peptides. In this study, we further studied DM sensitivity of T1D-associated DQ 
molecules by peptidomic analysis. Compared to T1D nonassociated DQ1 and DQ6, the 
percentages of shared peptides among T1D-associated DQ molecules were significantly 
higher. There were greater numbers of nested peptide sets and long peptides (>20-mer) 
eluted from T1D-associated DQ molecules. Predicted peptide binding motifs of DQ2, 
DQ8, and DQ2/8 shared charged anchor residues, while hydrophobic anchors were 
present in DQ6 peptides. Competition binding assays comparing the eluted peptides from 
DM sensitive, dependent, or resistant groups showed that the binding affinities of the DM 
resistant and dependent peptides were consistently high; however, the DM sensitive 
peptides were complicated, in which some of the DM sensitive peptides were with 
relatively higher affinity, indicating that high affinity is necessary but not sufficient for 
DM editing resistance, and other mechanisms are also involved. Measurements of peptide 
dissociation rates and DM editing effects further confirmed that DM editing dominates 
the biological stability of MHCII-peptide complexes. The increased complex stability 
that formed with DM resistant or dependent peptides, combined with the poor DM 
editing effects on T1D-associated DQ molecules, illustrates the critical impact of DM 
editing on peptide repertoire and highlights the potential role of DM resistance in T1D-
associated DQ molecules in T1D etiology. Taken together, our new data further support 
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the hypothesis that DM resistance in T1D-associated DQ molecules affects the peptide 
repertoires, thus contributing to the pathogenesis of T1D. 
 
Introduction 
Human major histocompatibility complex class II (MHCII), especially the HLA-
DQ alleles, DQ2 (DQA1*0501/DQB1*0201) and DQ8 (DQA1*0301/DQB1*0302), are 
highly associated with type 1 diabetes (T1D), an autoimmune disease with the loss of 
insulin production due to self-destruction of pancreatic β cells [1-5]. However, the 
involved molecular mechanisms are still uncertain. The characteristics of the peptide-
binding groove of MHCII molecules, including both the anchor-pocket interaction and 
the conserved hydrogen-bond network between peptide and MHCII, contribute to the 
peptide binding and presentation on the antigen-presenting cell (APC) surface [6]. 
Meanwhile, the repertoire of presented peptides by MHCII determines the selection or 
activation of CD4+ T cells [7]. Therefore, it is believed that the unique properties of T1D-
associated DQ molecules may contribute to the etiology of T1D. These properties, such 
as the unique peptide binding specificity and the different sensitivity to HLA-DM (DM) 
editing, will affect the presentation of key autoantigen epitopes associated with T1D and 
potentially differentiate the selection of the CD4+ T cell repertoire [8-11].  
DM plays a critical role to accelerate peptide exchange in the peptide-binding 
groove of MHCII [12]. Various findings indicate that DM selectively releases the lower 
affinity peptides and helps the loading of higher affinity peptides (“DM editing”), 
therefore potentially favoring the presentation of stable MHCII-peptide complexes on the 
surface of APC [12-14]. However, less study has focused specifically on the T1D-
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associated DQ molecules; there is no direct evidence exploring the impact of DM editing 
in T1D-associated DQ molecules. Previously, van Lummel et al. expressed T1D-
associated cis-dimers DQ2 or DQ8, or the trans-dimer DQ2-8 (DQA1*0501/ 
DQB1*0302) or DQ8-2 (DQA1*0301//DQB1*0201) molecules in 293T cells and firstly 
revealed the peptide repertoire difference of these T1D-associated DQ molecules [15]. 
However, there is no endogenous DM or human invariant chain (Ii) expressed in 293T 
cells. Ii plays multiple roles in antigen presentation process. First, it is required for the 
translocation of MHCII molecules to late endosomal compartments, in which the Ii is 
enzymatically processed and other peptides are loaded with the help of DM [6, 7]. 
Second, the occupancy of the peptide-binding groove of MHCII molecules by the Ii-
derived CLIP peptides inhibits the early loading of peptides in the endoplasmic reticulum 
(ER) and/or the MHCII trafficking compartments [16, 17]. Therefore, the deficiency of Ii 
and DM expression in their system might skew the identified peptide repertoire of T1D-
associated DQ molecules, and the impact of DM editing on DQ peptide repertoire was 
also not considered.  
We previously expressed in 293T cells each of the T1D-associated DQ2, DQ8, or 
the trans-dimer, DQ2-8 or DQ8-2 molecules, in the absence or presence of Ii and/or DM. 
We concluded that these T1D-associated DQ molecules are relatively resistant to DM 
editing for the release of Ii-derived CLIP peptides; therefore potentially affecting the 
efficient loading of other peptides for the selection or activation of CD4+ T cells involved 
in T1D etiology [11]. To further investigate the peptide repertoires of each T1D-
associated DQ molecules and the impact of DM editing on peptide repertoires, we 
analyzed the peptidome of each DQ molecules identifying eluted peptides by the HPLC-
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MS/MS methods [18, 19]. We found that T1D-associated DQ molecules share several 
distinct characteristics that are not observed with T1D nonassociated DQ molecules. In 
addition, we determined that high affinity is necessary but not sufficient to confer 
resistance to DM editing in stable MHCII-peptide complexes. Our findings further 
confirmed that T1D-associated DQ molecules are with distinct characteristics that may 
contribute to the pathogenesis of T1D.  
 
Results 
The impact of Ii and DM on the DQ bound peptide repertoire 
To investigate the impacts of Ii and DM editing on T1D-associated DQ molecules 
peptide repertoires, we eluted DQ bound peptides from each group of 293T cells (18 cell 
lines) expressing each of the DQ (DQ-only), DQ+Ii (-DM), or DQ+Ii+DM (+DM) 
molecules that we previously generated [11]. Interestingly, with the identified variable 
numbers of unique peptides in each cell lines, there was relatively little overlap of 
peptides between DQ-only and DQ+Ii, or DQ and DQ+Ii+DM samples (Figure 3.1A). It 
was also found that the sources of eluted peptides are apparently different when we 
compared the cells expressing DQ (Figure 3.S1, upper panel) with the cells expressing 
DQ+Ii (Figure 3.S1, middle panel), or with the cells expressing DQ+Ii+DM (Figure 3.S1, 
bottom panel); however, there is no visible source difference between the DQ+Ii and 
DQ+Ii+DM samples. These results suggested that expression of Ii has a major impact on 
the DQ bound peptide repertoire. Similarly, the small fraction of unique peptides that 
overlapped between the DQ+Ii and DQ+Ii+DM samples indicated an apparent difference 
of DQ bound peptide repertoire that results from DM editing (Figure 3.1A). Moreover, 
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for the length of each DQ presented peptides, we can rarely identify long (>20-mer) 
peptides from the DQ cell samples, but we can identify many longer peptides from cells 
expressing DQ+Ii or DQ+Ii+DM (Figure 3.1B and Figure 3.S2). In addition, the 
predicted peptide binding motifs from DQ-only eluted peptides (Figure 3.S4) are 
consistent with the motifs previously reported from experiments without Ii coexpression 
[15], but are different with the predicted motifs from cells expressing DQ+Ii or 
DQ+Ii+DM (Figure 3.1E and Figure 3.S4). Taken together, we conclude that the dual 
roles of Ii and the function of DM editing have a major effect on the bound peptide 
repertoires of each DQ molecule.  
 
Peptidomic analysis of T1D-associated DQ molecules that are  
less sensitive to DM editing  
As previously reported, when we coexpress DQ and Ii in 293T cells and compare 
the impact of DM editing among those DQ molecules, it was found that the T1D-
associated DQ molecules, including DQ2, DQ8, DQ2-8, and DQ8-2, are all relatively 
resistant to DM editing of Ii-derived CLIP peptides, with high surface CLIP levels on 
DM expressing cells; however, the T1D nonassociated DQ1 and DQ6 molecules are both 
highly sensitive to DM editing, with nondetectable surface CLIP on DM expressing cells 
[11]. These findings indicated that T1D-associated DQ molecules may have distinct DM 
editing sensitivity and the weakened DM editing sensitivity may change the T1D-
associated DQ bound peptide repertoires, and potentially affect the selection or activation 
of autoreactive CD4+ T cells. To further confirm this observation, we analyzed the 
peptidome of each T1D-associated DQ molecules and T1D nonassociated DQ1 and DQ6 
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molecules (Figure 3.1).   
We firstly compared the numbers of nested cores (two or more unique peptides 
sharing at least 8-mer of the same sequence) edited by DM, as defined by the nested 
cores identified in peptides from DQ+Ii but not from the DQ+Ii+DM samples. 
Interestingly, for DQ1 and DQ6, 82.1% and 88.9% of nested cores were edited by DM 
expression; while for the T1D-associated DQ2, DQ8, DQ2-8, and DQ8-2, there are only 
65.6%, 70.4%, 78.2%, and 62.7%, respectively, of nested cores edited by DM, showing a 
significant difference between T1D-associated and nonassociated DQ molecules (Figure 
3.1C).    
MHCII molecules can present both short and long peptides. The peptide-binding 
grooves of MHCII are opened at both sides, a unique property of MHCII distinguished 
from MHCI molecules [20, 21]. We analyzed the length of unique peptides eluted from 
each group of cells expressing Ii and T1D-associated or nonassociated DQ molecules in 
the absence or presence of DM expression. As expected, each of the DQ molecules can 
present both short (median length of ~15-mer) and long (~23-mer) peptides, and the 
majority of presented peptides by T1D nonassociated DQ1 and DQ6 molecules are short 
peptides in DQ+Ii samples; however, even greater percentages of long peptides were 
presented by T1D-associated DQ molecules in DQ+Ii samples. Surprisingly, when DM is 
expressed in these cell lines, the long peptides from T1D nonassociated DQ1 and DQ6 
molecules are edited by DM, as shown by a significant decrease in long peptides, while 
there are still a substantial number of long peptides retained with T1D-associated DQ 
molecules (Figure 3.1B). The different length distribution of the eluted peptides from 
DQ+Ii or DQ+Ii+DM cells between T1D-associated and nonassociated DQ molecules 
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further indicated that their DM editing sensitivity is different.   
Kooy-Winkelaar et al. previously reported gluten-specific T cells that are cross-
reactive with DQ8 and DQ2-8 molecules presenting the same peptides [22], indicating 
that the peptide-binding groove of DQ8 and DQ2-8 might share some similar 
characteristics. Van Lummel et al. also showed that some peptides can bind with multiple 
DQ molecules [15]. We calculated the number of same peptides eluted from cells 
expressing Ii and different DQ molecules (shared peptides) in the absence or presence of 
DM expression. Interestingly, in the absence of DM editing, there are 5.4% to 10.2% of 
DQ6 presented peptides shared in all of the other five DQ molecules and this is higher 
than the peptides shared among the other five DQ molecules (Figure 3.S3); however, in 
the presence of DM editing, the frequencies of shared peptides within T1D-associated 
DQ molecules are increased, between 4.8% and 10.1%, compared with the frequencies in 
DQ6 with a range between 2.0% to 3.6%, or in DQ1 with a range between 0.1% and 
0.4% (Figure 3.1D, highlighted). These data support the conclusion that T1D-associated 
DQ molecules share some similar properties in peptide binding. Moreover, the increased 
frequencies within the T1D-associated DQ molecules in the presence versus the absence 
of DM editing, while the decreased frequencies within the T1D nonassociated DQ 
molecules in the presence versus the absence of DM editing, indicates the enrichment of 
shared peptides that are resistant to DM editing (Figure 3.1D). This also supports our 
previous observation that some autoantigen-derived peptides can be presented by 
multiple different T1D-associated DQ molecules [11]. The results further indicate that 
DM editing is relatively less efficient in T1D-associated DQ molecules. They are also 
consistent with previous findings that these T1D-associated DQ molecules share some 
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similar peptide binding properties [15, 22], which may contribute to the T1D-associated 
different DQ molecules share with similar mechanism(s) in T1D etiology.  
To further analyze the differences between T1D-associated and nonassociated DQ 
molecules, we predicted the peptide binding motifs of each DQ molecule and compared 
the difference of motifs in the absence or presence of DM expression. We firstly 
compared the DQ8 peptide binding motif from the peptide dataset with the DQ8+Ii+DM 
samples with a previously published DQ8 motif, in which the peptide dataset were from 
naturally processed peptides using a B cell line generated from humanized NOD.DQ8 
mice [23, 24], to validate both the dataset we generated from 293T cells and the applied 
HPLC-MS/MS method [19]. As expected, the DQ8 peptide binding motif predicted with 
the DQ8+Ii+DM peptide dataset was very similar to the previously published DQ8 motif 
[24], with a dominant preference for acidic residues at P9, a preference for acidic residues 
at P1, and preference for smaller residues at P4 and P6, as well as proline and valine at P6 
(Figure 3.1E, panel 4). We then predicted the peptide binding motifs for each of the DQ 
molecules. As expected, within all of the six DQ molecules, there is clear evidence of 
DM editing effects between the motifs from DQ+Ii and DQ+Ii+DM samples, such as the 
enrichment of major anchor residues on P1 and P9 (Figure 3.1E and Figure 3.S4). All of 
the four T1D-associated DQ molecules share similar predicted peptide binding motifs, 
with the charged residues at the major anchor residues P1 and P9. With the DQ6 peptide 
binding motifs, these residues are not charged. Interestingly, the peptide binding motifs 
of T1D neutral DQ1 molecule showed similar characters as T1D-associated DQ 
molecules, but it is sensitive to DM editing [11]. It is possible that other mechanism(s) 
might be involved in its sensitivity to DM editing, as we previously proposed [8].  
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High peptide binding affinity is necessary but not sufficient for  
resistance to DM editing 
To study the relationship of peptide binding affinity and DM editing sensitivity, 
we firstly synthesized three categories of peptides that were eluted from DQ6 samples 
representing the DM resistant, DM dependent, or DM sensitive peptide group (Table 3.1 
and Figure 3.S5). To increase the grouping accuracy, we confirmed the recurrence of 
these peptides by the total hits of each peptide sharing the same nested core sequence 
within the raw dataset. As shown, for the group of DM sensitive peptides, they are only 
detectable in the DQ6+Ii sample in the absence of DM expression; for the DM dependent 
peptides, they are only detectable in the presence of DM expression, whereas for the DM 
resistant peptides, they are detectable in both situations (Table 3.1).  
We first measured the IC50 of each peptide, which is indicated by the 
concentration of peptides required for 50% inhibition of the loading of HA488 peptide to 
DQ6 in FP competition binding experiments [25]. As expected, all of the tested peptides 
from the DM resistant group, including ABP230, ABP634, CBC114, GRP198, and 
SCM57 can efficiently inhibit the loading of the indicator HA488 peptide with the 
measured IC50 value from 0.06 µM to 0.53 µΜ, compared with the unlabeled HA 
peptide with the measured IC50 at 1.63 µΜ (Figure 3.2A and 2E). Consistently, all of the 
peptides from DM dependent group, PRP348, TPP425, and NEP494, efficiently inhibited 
the loading of indicator HA488 peptide as well, with low IC50 values at 0.11 µΜ, 0.16 
µΜ and 0.07 µΜ, respectively (Figure 3.2B and 2E). While for most of the DM sensitive 
peptides, the IC50 values, from 2.67 µΜ to 18.03 µΜ, are significantly higher than those 
of the DM resistant and DM dependent groups (Figure 3.2C and 2E). These data 
 60 
confirmed that DM selectively favors the presentation of high affinity peptides by DQ6 
and the peptides with low binding affinity are sensitive to DM editing. 
Interestingly, the peptides LEP147 and CKA362 can also efficiently inhibit the 
binding of indicator peptides, with IC50 values at 0.32 µΜ and 0.12 µΜ, respectively 
(Figure 3.2D and 2E), even though these were grouped as DM editing sensitive due to the 
multiple hits in the DQ6+Ii but not in the DQ6+Ii+DM samples. The inconsistency of 
observed DM editing sensitivity and peptide binding affinity by IC50 measurement 
indicated that peptide affinity is not sufficient to predict resistance to DM editing in cells, 
and other factor(s) might be involved in the determination of MHCII-peptide sensitivity 
to DM editing. To support this hypothesis, we further measured the MHCII-peptide 
complex stability and the effect of DM editing using labeled DQ6-LEP147488 and DQ6-
CKA362488 complexes. Both of these complexes have significantly higher dissociation 
rates at different concentration of DM as compared with the DQ6-CBC114488 complex, 
which is resistant to DM editing (Figure 3.2 and Figure 3.3). This result is consistent with 
the observed peptide elution results showing that neither LEP147 nor CKA362 was 
detectable in the samples from cells with DM expression (Table 3.1). It also confirmed 
our hypothesis that high affinity is necessary but not sufficient for the resistance of DM 
editing. 
 
DM editing favors the formation of stable MHC II/peptide complex 
To further study the role of DM editing in the formation of stable MHCII/peptide 
complex, we labeled more of the synthesized peptides (Table 3.1) and preloaded each of 
them onto sDQ6 and measured the peptide dissociation rates. As expected, all of the DM 
 61 
sensitive peptides, CLIP, ABP625, LEP147, HA, and CKA362 showed significantly 
higher peptide dissociation rates in the presence of DM, while the DM resistant or DM 
dependent peptides, and the T1D-associated DQ2 and DQ8 that are relatively resistant to 
DM editing of CLIP peptide [11], consistently had significantly higher half-life, 
indicating higher complex stability, and lower peptide dissociation rates in the presence 
of DM (Figure 3.4A, Table 3.2, and Table 3.3). It is also consistent with data that was 
normalized relative to the interpolated intrinsic rates (Figure 3.4B and Figure 3.S6). 
These data confirmed that MHCII-peptide complexes formed with DM sensitive peptides 
are less stable in the presence of DM, and therefore unlikely to be presented by APC, 
while the MHCII-peptide complexes formed with DM dependent or resistant peptides are 
more stable, and likely to be immunologically dominant and involved in the selection or 
activation of CD4+ T cells. 
Interestingly, the intrinsic dissociation rates of DM sensitive peptides are variable 
and no significant difference was found between DM sensitive and DM insensitive 
(including DM resistant and DM dependent) groups; however, in the presence of DM, the 
complex stability and peptide dissociation rates are significantly different between DM 
sensitive and DM insensitive groups (Figure 3.4C, Table 3.2, and Table 3.3). These data 
further support the conclusion that peptide affinity is necessary but not sufficient for the 
formation of stable MHCII-peptide complexes in cells expressing DM. Taken together, 
these data confirmed the critical role of DM editing as a final checkpoint for the stability 





The association of DQ2 and DQ8 alleles with T1D raises several fundamental 
questions in this field regarding why these DQ alleles are associated with T1D and what 
unique properties of these T1D-associated DQ molecules, including the two trans-dimers 
DQ2-8 and DQ8-2, contribute to disease risk. In this study, we evaluated the properties of 
the T1D-associated DQ molecules by peptidomic analysis. We found further evidence, 
such as less editing of nested core numbers, significant DM resistance of longer peptides, 
combined with a relative resistance to DM editing of Ii-derived CLIP peptides that we 
previously reported [11]. It supports the conclusion that the four T1D-associated DQ 
molecules share distinct properties with relatively broad resistance to DM-mediated 
peptide editing, compared to the control molecules, T1D-protective DQ6 and T1D-
neutral DQ1, which are both sensitive to DM editing. We also systematically investigated 
the impact of DM editing effects on the selection of peptides that can form stable 
complex with MHCII and found that high affinity peptide binding is a necessary but not 
sufficient for the formation of DM-resistant MHCII-peptide complex. Collectively, our 
findings further highlight the critical role of DM editing in autoantigen presentation for 
the selection and/or activation of CD4+ T cells and its potential impact in the 
pathogenesis of T1D.  
Different mechanisms are involved in the relative DM editing resistance of T1D-
associated DQ2 and DQ8 molecules, as well as the trans-dimers DQ2-8 and DQ8-2 [8-
11]. The same DQ α chain (DQA1*0501) is shared between DQ2 and DQ2-8 molecules, 
in which there is a natural deletion of residue 53, and the insertion of Gly at this position 
restored its DM editing sensitivity [9]. In DQ8 and DQ8-2 molecules, extra hydrogen 
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bonds (H-bonds), with three in DQ8 and one in DQ8-2, were identified between the two 
helices of α and β chain and near to the DM contact site [11, 26]. Substitution on βE86A 
to disrupt two of the three H-bonds in DQ8 partially restored DM sensitivity, 
accompanied with decreased stability of the DQ8 complex [11]. Interestingly, for the two 
distinct mechanisms in DQ2 and DQ8, the same final output is shared: DM editing 
resistance. As described, we found more evidence for shared properties among the four 
T1D-associated DQ molecules in the current study. In particular, we found that there are 
more long peptides in all of the four T1D-associated DQ molecules that are resistant to 
DM editing. The biological impact of the DM resistant long peptides is unknown. It is 
also possible that these peptides result from incomplete antigen processing in 293T cells, 
but not in professional APC cells. However, the underlying mechanism(s) that is 
specifically linked to T1D-associated DQ molecules but not to T1D nonassociated DQ1 
or DQ6 molecules needs to be further investigated. It appears that long peptides may be 
more likely to be strong autoantigen agonists in T1D [27]. Potentially, the extra 
sequences in the long peptides might be beneficial for the competition of prebound CLIP 
peptides, as well as further disfavoring the interaction of DM and T1D-associated DQ 
molecules, based on the study of the spatial structure of DM and MHCII interaction [26].   
The measurement of peptide dissociation rates confirmed our peptide elution 
results, showing that all of the DM resistant or dependent peptides have significantly 
lower dissociation rates, indicating that these peptides can form biologically stable 
MHCII-peptide complexes. Consistently, these peptides show high binding affinity as 
illustrated by lower IC50 values. However, in the DM sensitive peptide group, some of 
the peptides that had significantly lower IC50 values, indicating high binging affinity, 
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were observed to be sensitive to DM editing. Intrinsic peptide dissociation rates were not 
found to be a reliable predictor of DM sensitivity (Table 3.2 and Table 3.3). These data 
indicated that peptide affinity is a necessary but not a sufficient determinant of biological 
MHCII-peptide complex stability in cells expressing DM. This is consistent with 
previous findings that in the MHCI pathway, MHCI-peptide complex stability is a better 
predictor than peptide affinity for CTL immunogenicity [28, 29], as well as in the MHCII 
pathway, where the stability of MHCII-peptide determines the clonal selection of CD4+ T 
cells [30, 31].  
Multiple factors might be involved in the determination of MHCII-peptide 
complex stability, such as the peptide affinity, peptide length (with positive or negative 
effects on peptide binding, and/or the interaction of DM and MHCII), the structure of 
peptide that favors or disfavors interaction of DM and the direct interaction of DM and 
MHCII affected by polymorphism of MHCII or DM, etc. As a final checkpoint, DM 
editing dissociates those peptides that form unstable MHCII-peptide complexes and 
favors the formation of stable MHCII-peptide complex. However, in the T1D-associated 
DQ molecules, the DM editing effects are less efficient due to the two distinct 
mechanisms [8, 9, 11]. In this situation, the peptide repertoire of T1D-associated DQ 
molecules could be skewed, and autoreactive CD4+ T cells might escape negative 
selection in thymus and be activated in peripheral as previously proposed [8, 11].  
In summary, in this study, we further confirmed that T1D-associated DQ 
molecules are relatively resistant to DM editing, a property that might affect the peptide 
repertoires involved in the selection and/or activation of autoreactive CD4+ T cells in 
T1D etiology. These findings will facilitate our understanding of the mechanism of 
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autoreactive CD4+ T cell development and improve our ability to design better strategy in 
early screening and treatment of T1D.   
 
Materials and Methods 
Cell lines used for peptide elution or the purification of  
soluble DQ and DM molecules 
 Three types of 293T cell lines that were previously generated and maintained in our 
lab were used for peptide elution [11]. The 293T-DQ cell lines (DQ only) express the full 
length α and β chains of DQ1 (DQA1*0101/DQB1*0501), DQ2 
(DQA1*0501/DQB1*0201), DQ6 (DQA1*0102/DQB1*0602), DQ8 
(DQA1*0301/DQB1*0302), or the trans-dimer DQ2-8 (DQA1*0501/DQB1*0302) or 
DQ8-2 (DQA1*0301/DQB1*0201), the 293T-DQ+Ii cell lines (DQ+Ii) express each DQ 
and the human Ii, and the 293T-DQ+Ii+DM (DQ+Ii+DM) cell lines express each DQ, Ii 
and the full length α and β chains of DM expression (DQ+Ii+DM). The transduced 293T 
cell lines expressing secreted soluble form of DQ molecules (sDQ), such as sDQ2, sDQ6, 
or sDQ8, were generated and maintained in the complete DMEM media, and the soluble 
proteins were purified as previously described [11]. The soluble DM (sDM) was purified 
from S2-sDM insect cells as previously described [32].  
 
Peptide elution and HPLC-MS/MS sequence analysis 
About 1x109 of each DQ only, DQ+Ii, DQ+Ii+DM transductants or the control 
cells were lysed and the DQ molecules were captured by anti-DQ antibody (SPVL3) 
immobilized with protein A beads. Bound peptides were eluted and further separated by 
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HPLC for HPLC-MS/MS analysis. The detail procedure and data process followed the 
previously described methods [18, 19]. 
 
DQ-eluted peptide alignment 
The sequences were aligned using a specialized expectation-maximization (EM) 
algorithm [33]. This EM algorithm focuses on the five major anchor residues with 
MHCII, P1, P4, P6, P7, and P9. Because each position has up to 20 different amino acids, 
there are 100 parameters in the alignment model. Two general steps, expectation (E) step 
and maximization (M) step, were undergone iteratively to build the alignment. The 
formulas for the E and M steps are listed as follows:  
E step: Calculate the Q function. !(θ|θ!) = ! Z∗ Z, θ! !log! Z∗ Z, θ!!∗   
M step: Maximize ! θ θ!  with respect to θ. θ!!! = arg!max! !(θ|θ!)  
where Z refers to the residues of the binding sites in the sequences, Z* refers to the 
unobserved binding positions, and θ is the alignment model. More details of this model 
can be found as previously described [33].  
 
Peptide synthesis and labeling 
The N-acetylated peptide CLIP (VSKMRMATPLLMQ) and HA 
(PRFVKQNTLRLAT) were previously labeled on lysine (underlined) with Alexa Fluor 
488 carboxylic acid, 2,3,5,6-tetrafluorophenyl ester (Molecular Probes) as described [32], 
and designated as CLIP488 and HA488, respectively.  The peptides, with the sequences 
listed in Table 3.1, were commercially synthesized (PepMic). Some of the peptides 
without lysine residue in the sequence, such as ABP625, CKA362, LEP147, CBC114, 
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PRP348, TPP425, ABP625, were further labeled on the N-terminus free amine with the 
same Alexa Fluor 488 carboxylic acid, 2,3,5,6-tetrafluorophenyl ester (Molecular 
Probes), following the manual and the purification method as previously described [32].  
 
Peptide competition experiment and IC50 calculation  
Peptide competition experiment, measured by fluorescence polarization (FP) 
assay, was performed as previously described [34], using HA488 as probe peptide. Briefly, 
150 nM of sDQ6, pretreated with thrombin beads as previously described [11], was 
incubated in FP buffer (100 mM citrate-phosphate buffer, 0.05% Tween-20, pH 5.0) with 
25 nM of HA488 probe peptide, 500 nM of sDM, and various concentration (0 to 20 µM, 
with a dilution factor of 5) of testing peptides (Table 3.1) as competitor peptides. The 
samples were incubated at 37oC for 18 h, then the FP signal were detected, as previously 
described [32]. The 50% inhibition concentration (IC50) of the testing peptides was 
calculated by fitting the curve of relative binding versus concentration of unlabeled 
testing peptide with the equation y = 1/[1+(pep)/IC50], in which the (pep) is the 
concentration of testing peptide, as previously described [34]. 
 
Fluorescence polarization assay and peptide dissociation  
rate calculation 
Thrombin-cleaved sDQ molecules were preloaded with each of the Alexa Fluor 
488 labeled peptides. Briefly, the sDQ and extra amount of each labeled peptides (1:5 
molar ratio) were incubated in FP buffer (pH5.0) at 37oC for 6 h (for sDQ6) or overnight 
(for sDQ2) with 50 nM or sDM, or at 37oC overnight without sDM (for sDQ8). Then, the 
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unbound peptides were removed by buffer exchange with 30-kD cut-off spin column 
(Millipore). In FP assay, 50 nM sDQ-488peptide complex, sDM (0 to 2000 nM) and 100 
µM competitor peptides were incubated in FP buffer and measured at 37oC with a Tecan 
Infinite F200 plate reader. FP value was normalized with the background (free 488peptide) 
FP signal. The data were processed with Prism 5.0 (GraphPad Software) and the DM 
catalytic peptide dissociation rate was calculated as previously described [32]. The 
peptide intrinsic dissociation rate was interpolated using a linear fit from the DM 
catalytic peptide dissociation rates with DM concentrations below 125 nM. 
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Figure 3.1. Peptidomic analysis of T1D-associated and nonassociated DQ molecules 
with the peptides eluted from 293T transductants. (A) Overlapping of the identified 
unique peptides eluted from DQ only (blue), DQ+Ii (yellow) and DQ+Ii+DM (orange) 
samples. (B) The distribution of peptide length in the absence or presence of Ii or DM 
editing. The dotted gray line separates the bimodal distributions with median lengths of 
~15 and ~23 amino acids. (C) The percentage of nested core numbers that were edited by 
DM. The significance between T1D-associated and nonassociated DQ molecules are 
shown with *, P=0.043, two-tail T-test, unpaired. The bottom left illustrated the 
population of peptides that was edited in the presence of DM expression. The bottom 
right showed an example of a nested core, in which multiple unique peptides share the 
same 9 amino acids core sequence as marked. (D) The frequency of unique peptides that 
were identified in common between samples from different DQ molecules in the presence 
of DM editing. The highlighted frequency indicated the increase of shared peptides 
within T1D-associated DQ molecules. (E) The predicted peptide binding motifs of each 
DQ molecules in the presence of DM editing. The numbers on the top of each motif 






Figure 3.2. Comparison of the peptide binding affinity among DM resistant, 
dependent and sensitive peptides by the measurement of IC50 in peptide 
competition experiment. (A) The percentage of indicator peptides HA488 bound to DQ6 
molecules with DM resistant peptides as competitors. Peptide competition experiment 
was performed in the presence of variant concentration competitor peptides, from 0 nM 
to 20000 nM, with 5 times dilution. After treated at 37oC for 18 h, five FP signal reads 
were averaged and normalized with the signal of bound indicators without competitor 
peptides. (B) The percentage of indicator peptides HA488 bound to DQ6 molecules with 
DM dependent peptides as competitors. (C) The percentage of indicator peptides HA488 
bound to DQ6 molecules with DM sensitive peptides as competitors. (D) The percentage 
of indicator peptides HA488 bound to DQ6 molecules with DM sensitive peptides that 
showing high affinity in competition assays as competitors. (E) Comparison of IC50 
among DM resistant, dependent and sensitive peptides. The asterisks mark the two 
peptides LEP147 and CKA362 that are not detectable in peptide elution experiments in 
the presence of DM expression but with high affinity in peptide competition experiments. 






Figure 3.3. Peptide dissociation rates and DM editing effects on LEP147 and 
CKA362 peptides. (A). The peptide dissociation rates of the four different peptides 
measured by FP experiments. The labeled DQ6/peptide complex was incubated with 20 
µΜ excess amount of unlabeled peptide and various concentration of DM (pH 5.0) and 
measured at 37oC by FP. (B) DM-catalyzed rate enhancements normalized for differences 







Figure 3.4. Effects of DM editing in different DQ-peptide complex stability. (A) 
Peptide dissociation rates of DM sensitive, resistant, and dependent peptides. The peptide 
dissociation rates of DQ8/CLIP, DQ2/CLIP and DQ6/CLIP were previously measured 
[11]. (B) DM-catalyzed rate enhancements normalized for differences in interpolated 
peptide intrinsic dissociation rates. (C) Distribution of IC50 that are measured in the 
presence of 500 nM of sDM versus the interpolated peptides intrinsic dissociation rates. 
(D) Distribution of IC50 versus DM-catalyzed peptide dissociation rates in the presence 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.S1. Distribution of the subcellular localization of proteins identified by the 
eluted unique peptides. The accession number of each protein that was identified by 
each of the eluted unique peptides was used to query the protein subcellular localization 
information from the UniProt human protein database (www.uniprot.org). The proteins 
with multiple localizations will be classified in combined groups. ER, endoplasmic 
reticulum; ER/G/L/En, the combined group of ER, Golgi, Lysosome, and Endosome; 
Multiple, the combined group that proteins are with multiple localizations other than the 
classified; Other, the group of proteins with unknown subcellular localization 





















































































































































































































































Figure 3.S2. Distribution of the length of unique peptides that were detected from 
each DQ samples. The unique peptides were eluted from DQ-only, DQ+Ii or 
DQ+Ii+DM samples and illustrated as the total number of peptides versus peptide length, 




















































Figure 3.S3. The frequency of unique peptides that were identified in common 
between samples from different DQ molecules in the absence of DM editing. This is 
supportive data for Figure 3.1D, showing no frequency difference of shared peptides 








Figure 3.S4. Predicted peptide binding motifs of each DQ molecules. Each of the DQ 
molecules peptide binding motifs was predicted using the eluted peptides from the 
transduced 293T-DQ samples in the absence (top panel) or presence (bottom panel) of 
human invariant chain expression. The numbers on the top of each motif showed the 























































Figure 3.S5. The classification of eluted peptides for their sensitivity to DM editing. 
The unique peptides eluted from DQ+Ii samples were not DM edited, while the peptides 
eluted from DQ+Ii+DM samples were DM edited. Based on the overlapping of two types 
of peptides, DM sensitive peptides represent the group of peptides that are in DQ+Ii 
samples but not in DQ+Ii+DM samples (yellow); DM dependent peptides represent the 
group of peptides that are in DQ+Ii+DM samples but not in DQ+Ii samples (red); DM 
resistant peptides represent the group of peptides that are in both samples (orange), 








Figure 3.S6. DM-catalyzed rate enhancements in DQ6/ABP625 complex. The DM 
editing effect is represented with the DM-catalyzed peptide dissociation rate normalized 
for fold enhancement with the interpolated intrinsic peptide dissociation rates. Data 
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Cutting Edge: HLA-DM Functions through a Mechanism
That Does Not Require Specific Conserved Hydrogen
Bonds in Class II MHC-Peptide Complexes1
Zemin Zhou,2*§ Kari A. Callaway,2* Dominique A. Weber,† and Peter E. Jensen3*‡
HLA-DM catalyzes peptide dissociation and exchange
in class II MHC molecules through a mechanism that
has been proposed to involve the disruption of specific
components of the conserved hydrogen bond network
in MHC-peptide complexes. HLA-DR1 molecules with
alanine substitutions at each of the six conserved H-
bonding positions were expressed in cells, and suscepti-
bility to DM catalytic activity was evaluated by measur-
ing the release of CLIP. The mutants !N62A, !N69A,
!R76A, and "H81A DR1 were fully susceptible to
DM-mediated CLIP release, and "N82A resulted in
spontaneous release of CLIP. Using recombinant solu-
ble DR1 molecules, the amino acid "N82 was observed
to contribute disproportionately in stabilizing peptide
complexes. Remarkably, the catalytic potency of DM
with each "-chain mutant was equal to or greater than
that observed with wild-type DR1. Our results support
the conclusion that no individual component of the con-
served hydrogen bond network plays an essential role in
theDMcatalytic mechanism. The Journal of Immunol-
ogy, 2009, 183: 4187–4191.
C lass II MHC molecules initially assemble with thechaperone invariant chain (Ii)4 followed by transportto endosomal compartments and proteolytic cleavage
of Ii, leaving a fragment, CLIP, largely buried in the peptide-
binding groove (1). HLA-DM catalyzes CLIP dissociation and
peptide exchange reactions in class II molecules, accelerating
the loading process for peptide Ags (2–4) and editing the rep-
ertoire of peptides presented to CD4! T cells. DM is a non-
polymorphicMHC class II protein that is structurally similar to
other class II molecules (5). However, DM does not have the
capacity to bind peptide Ags, and it functions as a chaperone-
catalyst, stabilizing peptide-free (“empty”) class II molecules (6)
and accelerating CLIP dissociation and peptide exchange
through a mechanism that involves transient direct physical in-
teraction with class II-peptide complexes. DM accelerates the
rate of dissociation of all peptides (7), not just CLIP, but cata-
lytic potency differs depending on the kinetic stability of the
complex (7–10) and other less defined features of the complex
(11–13). The capacity of DM to differentially “edit” peptide
complexes has important biological implications through skew-
ing of the repertoire of foreign and self-peptide complexes avail-
able for activation or tolerance induction in CD4! T cells.
The structural basis for the DM catalytic mechanism remains
poorly understood. The general orientation of the physical in-
teraction between DM and substrate MHC class II molecules
(i.e., HLA-DR) has been defined by using mutational and
cross-linking approaches (14–16). It is likely that DM prefer-
entially binds to and stabilizes a relatively unpopulated confor-
mational isomer of MHC class II-peptide complexes, charac-
terized by a loss or weakening of noncovalent interactions that
stabilize peptide binding (7, 17, 18). Two general sets of inter-
actions are largely responsible for peptide binding: 1) peptide
sequence-dependent interactions between peptide side chains
(anchors) and subsites or “pockets” in the peptide-binding
groove; and 2) a conserved hydrogen bond network formed by
nonpolymorphic amino acids in the MHC protein and main
chain atoms in bound peptide (19). The anchor-pocket inter-
actions are primarily responsible for determining peptide-bind-
ing specificity, whereas the conserved hydrogen bond network
provides a basal contribution to stability and constrains the ori-
entation of peptide in the binding site. Destabilization of con-
served hydrogen bonds has been hypothesized to be a primary
component of the DM catalytic mechanism (5, 7, 20, 21). This
is attractive because the hydrogen bond network is a conserved
feature, consistent with the universal capacity of DM to accel-
erate the dissociation of peptide complexes. There is strong ev-
idence that the network contributes greatly to stabilizing pep-
tide complexes (22, 23). In addition, this mechanism would
account for the results indicating that catalytic potency is
inversely proportional to kinetic stability (7). If one or more
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conserved hydrogen bonds were the primary target for disrup-
tion in the catalytic mechanism, one might predict that the en-
ergy of stabilizationwould be reduced by an approximately con-
stant factor independent of the sequence of the bound peptide.
Indeed, Narayan et al. recently proposed that DM specifically
targets the hydrogen formed by the conserved histidine at po-
sition !81 in MHC class II molecules (21). HLA-DR1 mole-
cules with an asparagine substitution at this position were re-
ported to form highly unstable peptide complexes, and peptide
dissociation was not further enhanced by DM, possibly because
DM cannot further disrupt a hydrogen bond that does not exist
in the mutant molecule.
In the present study, two approaches were used to systemat-
ically analyze the effect of conserved hydrogen bond-disrupting
mutations on DM catalytic potency. We postulated that muta-
tional disruption of specific hydrogen bonds targeted in the cat-
alytic mechanism would result in reduced catalytic potency,
consistent with the results reported by Narayan et al. (21). In-
stead, our results indicate that the conserved hydrogen bond
formed by histidine !81 is not a primary target in the DM cat-
alytic mechanism. Indeed, our findings support the conclusion
that none of the conserved hydrogen bonds is a critical target
necessary for DM-catalyzed peptide dissociation.
Materials and Methods
Expression of mutant DR1 molecules in T2 cells
Full length DR1" and DR1! (DRA*0101/DRB1*0101) and mutant con-
structs were cloned into the retroviral vectors pLPCX or pLXSN (Clontech).
Constructs encoding full-length DM "- and !-chains were fused with the
FMDV.2A sequence (24) by PCR. The DM!-2A-DM" construct was cloned
into the retroviral vectorMigR1, which has a GFPmarker driven by an internal
ribosomal entry site. The T2 and Phoenix cell lines were obtained from the
American Type Culture Collection. High-titer retroviral supernatants were
generated by transfection of Phoenix cells with pLPCX-DR!, pLXSN-DR" or
MigR1-DM!-2A-DM" (25). T2-DR"-DR! double positive cell lines were
obtained by DR" retroviral infection and puromycin selection, followed by
DR! retroviral infection and G418 selection (Invitrogen). To coexpress DM,
cells expressing wild-type (WT) or mutant DR1 were infected with DM!-2A-
DM" retrovirus and sorted for GFP expression with a FACSVantage cell sorter
(BD Biosciences).
Abs and flow cytometry
Fluorophore-conjugated mAbs to HLA-DR (L243), CLIP (CerCLIP), and
HLA-DM (MaP.DM1) and isotype-matched negative control mAbs were pur-
chased from BD Pharmingen. Cell surface staining was performed with a combi-
nation of mAbs according to the standard procedures. Intracellular staining was
performed using BD Cytofix/Cytoperm kit according to the manufacturer’s in-
structions (BDBiosciences). Stained cells were analyzed on a FACScan flow cytom-
eter (BD Biosciences) and data were analyzed with FlowJo 8.4 software.
Expression and purification of soluble (s) DR1 (sDR1) and sDM
Stable S2 transfectants expressing sDR1A (residues 1–192) and sDR1B (resi-
dues 1–198) were induced for 7 days in BD BaculoGold Max-XP serum-free
medium (BD Biosciences) with 1 mM CuSO4. Cell culture supernatant was
collected by centrifugation, sDR1 was purified with L243 mAb affinity chro-
matography, and aggregates were removed using a TSK-GEL G3000SW ana-
lytical gel filtration column. Soluble DM was purified from supernatants of S2
transfectants as described (4, 14).
Peptide labeling and sDR1-peptide complex formation
The peptides HA (PRFVKQNTLRLAT) and CLIP (VSKMRMATPLLMQ)
were commercially synthesized with theN terminus acetylated. Alexa Fluor 488
carboxylic acid, 2,3,5,6-tetrafluorophenyl ester was used to covalently attach
the Alexa Fluor 488 fluorophore to the lysine residue (underlined in the se-
quences above) in the peptide. Labeled peptides were purified by reverse-phase
chromatography and labeling was confirmed by MALDI mass spectrometry.
sDR1-peptide complexes were formed by incubating sDR1 (5–10#M)with 50
or 250 #M peptide in 10 mM citrate-phosphate buffer (pH 5.0) and 150 mM
NaCl. After an overnight incubation at 37°C, complexes were purified on a
TSK-GEL G3000SW analytical gel filtration column and concentrated with a
micron centrifugal device.
Fluorescence polarization peptide dissociation assays
To measure peptide dissociation rates, 50 nM sDR1 complexes containing Al-
exa Fluor 488-labeled peptide was incubated with 20 #M unlabeled peptide in
the absence or presence of sDM (0.25–2 #M). Assays were performed at 37°C
in 10 mM citrate-phosphate buffer (pH 5.0), 150 mM NaCl, and 0.05%
Tween 20 in a final volume of 75 #l. All reactions were conducted in Corning
384-well, low-flange, black, flat-bottom, polystyrene NBSmicroplates. To pre-
vent evaporation during measurements, 10 #l of mineral oil was layered over
the reactions and the plate was covered with a VIEWseal plate seal (Greiner
Bio-One). Fluorescence polarization measurements were made using a Tecan
Infinite F200 plate reader equipped with polarizers and two 485-nm (#20 nm)
bandwidth filters for excitation and two 535-nm (#25 nm) bandwidth filters
for emission. A total of 25 flashes were used for each reading and the integration
time was set to 20 #s. The program i-Control was used to collect data and to
calculate the fluorescence polarization, p, which is defined as p$ (IV% GIH)/
(IV & GIH), where IV and IH are the intensity of the emission at polarizations
both parallel and perpendicular to the excitation source, and G is a factor to
correct for instrumental differences in detecting emission components. The ex-
periments containing complexes of WT, W61A, or H81A DR1 were moni-
tored for 1000 cycles of 432 s each. For assays containing the 488HA-N82A
complex, the reactions weremonitored for 1000 cycles of 8 s each in the absence
of sDM and for 600 cycles of 3 s each in the presence of sDM. Rate constants
were obtained by fitting the data points to the single exponential decay equation
p $ Ae%kt & C using Prism 4.0 (GraphPad Software).
Results and Discussion
Susceptibility of mutant HLA-DR molecules to DM-catalyzed CLIP
dissociation in cells
We mutated the amino acids in MHC class II molecules that par-
ticipate in conserved hydrogen bonds to evaluate the effect on DM
catalytic activity. As an initial approach, mutant HLA-DR1 mol-
ecules were expressed in T2 lymphoid cells in the presence or
absence of DM. T2 cells express endogenous Ii but not DR or DM.
Retroviral expression constructs were generated encoding DR1
molecules with alanine substitutions for each of the three con-
served MHC class II "-chain amino acids that form hydrogen
bonds, "N62A, "N69A, and "R76A (Fig. 1), thus preventing the
FIGURE 1. The conserved hydrogen bond network in class II MHC-pep-
tide complexes. The binding site of DR1 is represented as a ribbon diagram and
the backbone of bound peptide is shown as a stick representation. Hydrogen
bonds with main chain atoms of bound peptide are shown as yellow dashed
lines. Main chain atoms of amino acids at DR1 positions "51 and "53 mediate
hydrogen bonds, whereas conserved side chains form hydrogen bonds at other
positions in the MHC molecule. The figure was generated with PyMOL soft-
ware (www.pymol.org; PyMOLmolecular graphics system; DeLano Scientific)
using Brookhaven Protein Data Bank coordinate file 1DLH (19).
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formation of specific hydrogen bonds. Cell lines were generated
expressing comparable levels of total and cell surface DR1. High
levels of CLIP were present on the surface of cells expressing WT
DR1 in the absence of DM (Fig. 2). Spontaneous dissociation of
CLIP from DR1 is inefficient, and DM is required to catalyze CLIP
dissociation and replacement with other peptides. CLIP expression
was markedly reduced on cells coexpressing DM with WT DR1,
reflecting normal DM catalytic activity. High CLIP levels were
also present on cells expressing each of the !-chain mutant DR1
molecules, !N62A, !N69A, or !R76A, and this phenotype was
reversed in cells coexpressing DM (Fig. 2). Thus, none of the five
conserved hydrogen bonds formed by the amino acids !N62,
!N69, and !R76 is critical for the stable association of CLIP with
DR1, and each mutant is fully susceptible to DM-catalyzed CLIP
dissociation.
To evaluate the conserved hydrogen bonds formed by the MHC
class II "-chain (Fig. 1), alanine substitutions were engineered at
each of the three conserved positions to generate "W61A, "H81A,
and "N82A DR1 molecules. The mutants were observed to as-
semble efficiently with Ii (data not shown). In the absence of DM,
high levels of CLIP were present on cells expressing "W61A or
"H81A DR1 (Fig. 3). By contrast, CLIP was completely absent
from the surface of cells expressing "N82A DR1, suggesting that
the bidentate hydrogen bonds formed by "N82 play a dispropor-
tionate role in stabilizing CLIP-DR1 binding.
CLIP levels were markedly reduced on cells coexpressing DM
and "H81A DR1 (Fig. 3), demonstrating that DM can efficiently
catalyze CLIP dissociation from DR1 complexes lacking the "H81
hydrogen bond, a result that was further confirmed with the aspar-
agine substitution mutant "H81N (supplemental Fig. S1),5 directly
contradicting the conclusions of Narayan et al. (21). "H81A DR1
molecules in DM-expressing cells were stable in SDS detergent,
evidence that CLIP is exchanged for high affinity peptides in these
cells (data not shown). We were also interested in determining
whether the histidine at "81 influences the pH-dependence of DM-
catalyzed peptide binding, which is optimal at acidic endosomal
pH (2–4). The "H81A and "H81N mutations had little or no effect
on the pH-dependence of DM-catalyzed peptide binding (supple-
mental Fig. S2).
By contrast to the "H81 mutations, "W61A DR1 molecules
appeared to be partially resistant to DM-mediated CLIP dissocia-
tion. This was true even when subpopulations that gated for iden-
tical expression of DR and DM were analyzed. Thus, the hydrogen
bond formed by "W61 was a candidate target in the DM catalytic
mechanism. The capacity of DM to catalyze CLIP dissociation
from "N82A DR1 could not be evaluated with this approach be-
cause of the high rate of spontaneous dissociation, leaving "N82 as
an additional candidate.
Effect of MHC class II "-chain mutations on DM catalytic potency
To further evaluate the role of conserved hydrogen bonds in-
volving the MHC class II "-chain in the DM catalytic mecha-
nism, we generated soluble recombinant DR1 and "W61A,
5 The online version of this article contains supplemental material.
FIGURE 2. Effect of mutations in conserved positions in the DR1 !-chain
on susceptibility to DM-mediated CLIP release. Expression of DR and CLIP
on the surface of T2 cells expressing WT or mutant DR1 molecules in the ab-
sence (bottom panels) or presence (middle panels) of DM was measured by flow
cytometry with mAbs L243 (DR) and CerCLIP (CLIP). Total cellular expres-
sion of DM was measured in permeabilized cells by flow cytometry using the
mAb MaP.DM1 (top panels).
FIGURE 3. Effect of mutations in conserved positions in the DR1 "-chain
on susceptibility to DM-mediated CLIP release. Expression of DR and CLIP
on the surface of T2 cells expressing WT or mutant DR1 molecules in the ab-
sence (bottom panels) or presence (middle panels) of DM was measured by flow
cytometry. GFP fluorescence was determined by flow cytometry as a surrogate
measure of DM expression (top panels).
FIGURE 4. Effect of mutational disruption of DR1 "-chain hydrogen
bonds on DM catalytic potency. a–e, Preformed complexes (50 nM) of Alexa
Fluor 488-labeled HA or CLIP peptides bound to mutant sDR1 were incu-
bated with excess unlabeled peptide (20 #M) and various concentrations of
soluble DM (pH 5.0) at 37°C. Peptide dissociation rates were measured using
a fluorescence polarization assay as described inMaterials and Methods. f, Data
for mutant sDR1 molecules are compared with WT sDR1 in a log-log plot of
peptide dissociation rates vs DM concentrations. g, DM-catalyzed rate en-
hancements normalized for differences in intrinsic peptide dissociation rates.
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!H81A, and !N82Amutant proteins. A fluorescence polariza-
tion assay was used to quantify the impact of DM on the kinet-
ics of peptide dissociation. A DM concentration-dependent ac-
celeration of the rate of peptide dissociation was observed with
WT DR1 complexes containing the high affinity peptide HA
(Fig. 4a). The !H81Amutation had essentially no effect on the
intrinsic stability of the DR1-HA complex (Table I), and the
mutation did not reduce the potency of DM in catalyzing pep-
tide dissociation (Fig. 4, c, f, and g). Indeed, catalytic potency
was somewhat greater for !H81A compared with WT DR1.
Thus, the hydrogen bond formed by !H81 does not play a ma-
jor role in stabilizing DR1-peptide complexes and is not an es-
sential target in the DM catalytic mechanism.
The !W61A mutation reduced peptide complex stability
with an !5-fold increase in the intrinsic HA dissociation rate
(Table I). However, DM catalytic potency was not reduced,
even after normalization for the effect on the intrinsic peptide
dissociation rate (Fig. 4, d, f, and g). These results contrasted
with the finding that CLIP release from !W61A DR1 was rel-
atively resistant to DM in cells (Fig. 3). We considered the pos-
sibility that DM might selectively catalyze the dissociation of
HA but not CLIP from !W61A DR1. However, DM was ob-
served to catalyze the dissociation of a variant CLIP peptide
from !W61A DR1 (Fig. 4e) with potency similar to that ob-
served for HA (Fig. 4f). Full-length !W61A DR1-CLIP com-
plexes were also highly susceptible to DM (data not shown).
Although we did not observe any gross alteration in endosomal
colocalization of !W61A DR1 with DM (data not shown), it
seems likely that this mutation affects the capacity of DR1-
CLIP complexes to interact optimally with DM in T2 cells, ei-
ther by impacting colocalization in membrane subdomains or
through an effect on trafficking kinetics (26).
Strikingly, the !N82A mutation was observed to increased
the intrinsic HA dissociation rate by "3000-fold (Table I).
This is consistent with the spontaneous release of CLIP ob-
served with this mutant expressed in cells (Fig. 3). Previous
studies with mouse class II molecules support the idea that
!#82 may in general have a dominant role in stabilizingMHC
class II-peptide complexes (23, 27). Remarkably, despite the
very rapid spontaneous dissociation of HA from !N82A DR1,
DM further accelerated peptide dissociation (Fig. 4, b and f ).
The catalytic potency was similar to that observed with WT
DR1, even with data normalized for intrinsic rates (Fig. 4g).
Thus, the two hydrogen bonds formed by !N82 appear to be
critical for stabilizing DR1-peptide complexes, yet they are not
essential targets in the DM catalytic mechanism.
Concluding Remarks
In addition to the nine hydrogen bonds that we analyzed by
mutational analysis in the current study, three conserved hydro-
gen bonds that interact with main chain atoms in the amino
terminus of bound peptide are contributed by the main chain
atoms of amino acids at positions "51 and "53 in DR1 (Fig. 1)
(19). The potential role of these hydrogen bonds in the DM
catalytic mechanism cannot be analyzed by mutation. How-
ever, Stratikos et al., used peptide truncation and amide
N-methylation to prevent the formation of these hydrogen
bonds in DR1-HA peptide complexes (20), demonstrating that
DM catalytic potency was enhanced!6- to 9-fold with peptide
complexes lacking one or more of these hydrogen bonds. They
observed only minor effects on catalytic potency with N-meth-
ylated peptide analogues designed to disrupt each of four addi-
tional conserved hydrogen bonds (20). It is possible that the
disruption of hydrogen bonds mediated by "51, "53, or !81
increases DM binding affinity by increasing DR structural flex-
ibility, resulting in small increases in DM catalytic potency.
The central conclusion of the current study is that no indi-
vidual component of the conserved hydrogen bond network
plays an essential role in the DM catalytic mechanism.
DM catalytic activity is preserved or even enhanced with the
artificial disruption of any component of the conserved net-
work. Given the universal capacity of DM to catalyze peptide
dissociation, the conserved network has been an attractive po-
tential target in the catalytic mechanism. If this is the case,
however, individual components of the network must play a
redundant role. It has become increasingly clear that MHC
class II-peptide binding involves cooperative interactions
throughout the peptide-binding groove, and the hydrogen
bond network appears to be relatively isolated energetically
from the anchor-pocket interactions (27–29). It is possible, for
example, that DM might initially promote the destabilization
of N-terminal hydrogen bonds, leading to a global change in
conformation that destabilizes multiple elements of the hydro-
gen bond network. Removing any subset or single H-bond does
not prevent DM from having its catalytic effect, but instead, it
might even enhance the catalytic impact. Alternatively, DM
might reduce the stability of peptide complexes by impacting
other global features such as the dynamics or general structural
flexibility of the peptide-binding groove, possibly by altering
the interaction of the groove domain with the supporting Ig
domains.
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T1D is an autoimmune disease characterized by the self-destruction of pancreatic 
β cells. Based on decades of studies on the etiology of T1D, it is widely accepted that 
autoreactive CD4+ T cells initiate this self-destruction [1, 2]. However, the underlying 
triggers and mechanisms that include both environmental and genetic factors are 
extremely complicated. Genome wide association analysis and genotyping studies 
indicated that individuals with MHCII of DQ2 or DQ8 haplotypes, especially DQ2/DQ8 
heterozygotes, with the expression of both DQ2 and DQ8, and the assembling of trans-
dimers DQ2-8 and DQ8-2 molecules, are associated with significantly higher risk of T1D 
[3-9]. To illustrate the molecular mechanism that is involved in the development of 
autoreactive CD4+ T cells, we investigated the unique properties of these T1D-associated 
DQ molecules, compared with the T1D nonassociated DQ6 and DQ1 molecules, and the 
molecular mechanism of DM editing and its potential role in T1D.  
In Chapter 1 of this thesis, we summarized the role of MHCII, especially the 
unique structural characteristics of T1D-associated DQ molecules, and the role of DM 
mediated peptide editing in antigen presentation and in the selection and/or activation of 
autoreactive CD4+ T cells in T1D.  Chapter 2 was focused on the characteristics of T1D-
associated DQ2 and DQ8 molecules with demonstration that the presentation of invariant 
chain (Ii) derived CLIP peptides is relatively resistant to DM editing. Chapter 3 of this 
thesis further addresses the characteristics of these T1D-associated DQ molecules by 
peptidomic analysis, illustrating the critical role of DM editing in MHCII presented 
peptide repertoires, while the DM editing function is less efficient in T1D-associated DQ 
molecules. In Chapter 4, we describe experiments that disproved the prevailing 
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hypothesis that hydrogen bonds in the conserved hydrogen network in MHC-peptide 
complexes are specifically disrupted in the DM catalytic mechanism.  
 
Role of Invariant Chain in MHC Class II Antigen  
Presentation Pathway 
 Ii is associated with MHCII molecules to help transport MHCII molecules into the 
late endosomal compartment. The binding of Ii with the peptide-binding region of 
MHCII molecules also protects the peptide-binding groove from early loading of peptide 
from the endoplasmic reticulum (ER). After proteolytic cleavage, the Ii-derived CLIP 
peptide remains in the peptide-binding groove and needs to be released for the loading of 
other endogenous or exogenous peptides [10, 11]. Due to the highly polymorphic nature 
of MHCII, especially in the peptide-binding region, the interaction of Ii chain and MHCII 
can be distinct and lead to variable outputs. First, due to the accessibility of proteases 
affected by conformational variation in the Ii-MHCII complex, the events of proteolytic 
cleavage of Ii might be different. As supported in Chapter 2, most of the Ii-derived 
CLIP1 peptides were processed more efficiently in DQ1, with short or no N-terminus 
extensions in eluted CLIP1 peptides; however, most of the CLIP1 peptides eluted from 
the other DQ molecules contained long N-terminus extensions. This finding is consistent 
with the structural differences in the conformation of DQ1 near to the N-terminus of 
CLIP1 peptide, a region that may be more flexible than the other DQ molecules, as we 
discussed in Chapter 1. Second, the binding affinity of Ii-derived CLIP peptides with 
different MHCII molecules might be distinct. In the presence of DM editing, CLIP 
peptides were efficiently released from DQ1 or DQ6 molecules; however, in T1D-
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associated DQ molecules, large quantities of retained CLIP peptides were found on the 
cell surface or associated with DQ molecules in peptide elution assay in the presence of 
DM editing. As a result, the CLIP peptide being presented on the APC surface either 
directly interacts with TCR or indirectly affects the efficient presentation of other 
peptides. Third, the alternative binding or rebinding of Ii-derived CLIP peptides might be 
different, including the well-defined CLIP1 and CLIP2 registers, which might also affect 
the peptide repertoire of MHCII. A large quantity of CLIP2 peptides were identified 
bound with DQ2 molecules but not with the other DQ molecules in the presence of DM 
editing, although the direct biological relevance of CLIP2 peptides in T1D etiology is still 
unknown, as discussed in Chapter 2 and previously reported [12, 13]. Moreover, the 
alternative binding of Ii-derived peptides, including register shifting [14-16] and the 
bidirectional binding of CLIP peptides [17, 18] might also affect the peptide repertoire 
due to the polymorphism of peptide binding groove region.  
 The relevance of Ii in the development of autoreactive CD4+ T cells still need to 
be determined. In previous studies, high levels of Ii-derived CLIP1 and CLIP2 peptides 
have been detected in T1D-like NOD mice [19]. Patients with T1D also show relatively 
high levels of CLIP on the surface of lymphocytes [20]. Celiac disease patients with DQ2 
expression are also associated with high CLIP2 levels [12, 13, 21]. It is notable that the Ii 
deficiency in Ii-/- NOD mice completely protects NOD mice against T1D [22]. In 
Chapter 2 of this thesis, we also found high levels of Ii-derived CLIP1 peptides retained 
on T1D-associated DQ molecules, and a large amount of CLIP2 peptides associated with 
DQ2 molecules. The coincidence of high level of CLIP with T1D-associated DQ 
molecules, as well as with T1D individuals, might be a general indicator of inefficient 
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DM editing with T1D-associated DQ molecules, or the CLIP peptides are high affinity 
binders to these T1D-associated DQ molecules. Both of these mechanisms have the 
potential to change the peptide repertoire of T1D-associated DQ-peptide complexes and 
might mediate alternative selection or activation of autoreactive CD4+ T cells involved in 
T1D, as we proposed in Chapter 1. Alternatively, it is also plausible that Ii does not 
directly contribute to the etiology of T1D, which is supported by the observation that DM 
knockout NOD mice are completely protected against T1D, despite high expression 
levels of MHCII-CLIP complexes [23]. To directly address the potential role of Ii or the 
Ii-derived CLIP peptides in T1D etiology, it would be valuable but challenging to directly 
estimate the role of CLIP peptides in thymic selection of autoreactive CD4+ T cell or the 
identification of CLIP cross-reactive autoreactive CD4+ T cells in T1D individuals.    
 
Role of DQ Molecules in Autoreactive CD4+ T Cell  
Development and Activation 
 The fate of thymocytes is determined by the affinity of expressed T cell receptor 
(TCR) that interacts with the antigen-presenting cell (APC) surface self-peptide-MHC 
complexes. Those thymocytes with high affinity TCR will be deleted by negative 
selection; the remaining T cells are theoretically self-tolerant [24, 25]. However, it is 
known that a fraction of autoreactive T cells escaped negative selection through several 
potential mechanisms, as we summarized in Chapter 1.  
In our research, we found that the DM-mediated peptide editing of T1D-
associated DQ molecules is inefficient, which is affected by the unique properties of 
T1D-associated DQ molecules. First, the polymorphisms of DQ alleles, especially in the 
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peptide binding groove region of T1D-associated DQ molecules, that may determine that 
T1D-associated DQ molecules favor selective binding of specific autoantigen-derived 
peptides. As shown by the peptide binding motifs that we predicted in Chapter 3, the 
major anchor residues at P1, P4, P6, P7, and P9 of the bound peptides are charged in 
T1D-associated DQ molecules; however, those anchor residues are nonpolar amino acids 
in the bound peptides of T1D protective DQ6 molecules. Second, the distinct structural 
characteristics in T1D-associated DQ molecules may make these molecules poor 
substrates for DM editing. As previously reported, a natural deletion of α53 in DQ2 
diminishes the sensitivity to DM editing [26]. Similarly, as we identified in Chapter 2 and 
Appendix B, the extra hydrogen bonds in the β chain of DQ8 contribute to the 
inefficiency of DM editing, and disruption of two hydrogen bonds in a DQ8-βE86A 
mutant protein significantly increased both the DQ8/peptide complex stability and 
sensitivity to DM editing.  
Based on these findings, we can conclude that the unique properties of T1D-
associated DQ molecules affect the DM editing efficiency and might change the peptide 
repertoires presented on the APC surface, which could deliver distinct strength of 
MHC/peptide signals to the TCR that may potentially be beneficial for the survival of the 
autoreactive CD4+ T cells in the thymus. Similarly, distinct signals could be delivered for 
the activation of autoreactive CD4+ T cells in the peripheral as well. In future studies, 
direct identification of autoreactive CD4+ T cells that are selected in the context of 
inefficient DM editing is required to further test this hypothesis. A humanized mice 
model with DQ2-α53R insertion transgene, or DQ8-βE86A mutation transgene to 
increase the DM editing sensitivity might be valuable to estimate the importance of DM 
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editing efficiency in the negative selection of autoreactive CD4+ T cells, especially its 
role in the pathogenesis of T1D or other autoimmune diseases, such as Rheumatoid 
Arthritis [27-30] and celiac disease [31-35].  
 
Molecular Mechanism of DM Editing and Its Effect 
 Two general sets of interactions contribute in the binding of peptide with MHCII, 
including peptide sequence-dependent interactions between peptide side chains (anchors) 
and subsites (pockets) in the peptide-binding groove, and a conserved hydrogen bond 
network formed by nonpolymorphic amino acids in the MHCII and main chain atoms in 
bound peptide [36]. It has been hypothesized that the destabilization of one or more of 
these conserved hydrogen bonds to be the primary event in the DM catalytic mechanism 
[37-42]. The conserved hydrogen bond formed between βH81 of the MHCII and the 
peptide backbone has been reported to dominate DM susceptibility [42]. To 
systematically analyze the effect of the conserved hydrogen bond network and further test 
this hypothesis, in Chapter 4, we mutated each of the residues in DR1 protein involved in 
the formation of hydrogen bonds with the backbone of bound peptides, postulating that 
mutational disruption of specific hydrogen bonds targeted by DM would result in reduced 
catalytic potency as previously reported [42]. Instead, our results confirmed that 
disruption of the conserved hydrogen bond formed by βH81 affected neither the intrinsic 
stability of the DR1-HA complex nor the potency of DM in catalyzing peptide 
dissociation, which is further confirmed by other groups [43, 44]. The mutation of other α 
or β chain residues involved in the formation of conserved hydrogen bonds with bound 
peptides further confirmed our conclusion that none of the conserved hydrogen bonds is a 
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critical target necessary for DM-catalyzed peptide dissociation.  
Interestingly, based on the increased intrinsic peptide dissociation rate and DM 
catalytic potency measured in βN82A mutation as reported in Chapter 4, even though the 
two hydrogen bonds formed by βN82 with the backbone of bound peptide are not the 
direct target in the DM catalytic mechanism, they are critical for stabilizing DR1-peptide 
complexes, which is consistent with previous findings [45, 46]. Molecular dynamics 
simulation and mutagenesis analysis also suggested that βN82 is involved in stabilizing 
the nonreceptive structure of empty DR1 by narrowing of the peptide-binding groove 
close to the P1 pocket region with the formation of a critical hydrogen bond between αQ9 
and βN82 [44]. Moreover, structural analysis of DM-DR1 interaction further illustrated 
that the interaction of DM and DR1 mediates DR1 αE55 moving into the peptide-binding 
groove and forming a water-mediated hydrogen bond with βN82 [47].  Therefore, it is 
plausible that the two hydrogen bonds formed by βN82 are indirectly involved in 
hydrogen bonds exchange during the DM-MHCII interaction.  
 Mutagenesis and recent structural studies confirmed that the acidic concave 
surface of DM directly interacts with α chain of MHCII close to the P1 pocket, and barely 
with β chain of MHCII [47-51]. The DM-MHCII interaction involves a significant 
conformational rearrangement of peptide-binding groove, especially in the α53-65 region 
around the P1 pocket of MHCII [47-49], which is consistent with the predicted 
conformation of the peptide-binding groove in the bound, partially filled, or empty states 
in previous molecular dynamics simulation and recent thermodynamics studies [44, 52-
54]. The mechanism of DM-mediated MHCII peptide exchange includes the process of 
dissociation of prebound peptide, interaction with the empty MHCII, and the association 
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of new peptide. The mechanism of DM-catalyzed peptide dissociation has been 
investigated in the past two decades [40-43, 47-49, 54-59]. Different models have been 
proposed to understand the mechanism of DM-catalyzed peptide association or the role of 
DM to facilitate peptide loading, based on the potentially different roles of DM in 
interacting and/or stabilizing empty MHCII, converting nonreceptive to receptive form 
MHCII, or formation of a peptide-loading DM-MHCII complex [60-64]. Recently, 
Stern’s group reevaluated these potential roles of DM in the peptide association process 
and concluded that DM neither mediates the conversion from nonreceptive to receptive 
forms of MHCII, nor the stabilization of empty MHCII, and this study supported a 
previously reported model in which DM contributes to peptide association by formation 
of a peptide-loading DM-MHCII complex between DM and empty MHCII [64, 65].   
According to the current evidence relating to DM in MHCII peptide dissociation 
and association processes, DM might play a role as a sensor to check the conformational 
flexibility of MHCII complexes. In this model, DM preferentially binds to MHCII with a 
flexible conformation, including conformational states of MHCII with an empty peptide-
binding groove, partially occupied or bound with weak ligand, but DM is disfavored in 
binding MHCII with inflexible conformations. The association of DM with unstable 
MHCII complexes may induce secondary conformational rearrangements, especially the 
rearrangement of several key residues around the P1 pocket and the exchange of 
hydrogen bonds in the conserved hydrogen network. This rearrangement may result in a 
thermodynamic “open” state with a broad conformation change in the whole peptide-
binding groove, favoring the release of if any prebound weak peptide and the acceptance 
of new peptide. The association of new peptide will further shape the conformation of 
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MHCII to increase the stability of the MHCII-peptide complex. The release of peptide 
and reloading of another peptide could reoccur if the peptide binding mediated 
conformational change is not enough to induce the dissociation of DM-MHCII 
interaction. If the peptide mediated conformational change is sufficient to stabilize the 
MHCII-peptide complex and that stable conformation is unfavorable for DM interaction, 
the dissociation of DM from MHCII-peptide complex will occur. 
 For T1D-associated DQ8 molecules, as studied in Chapter 2 and 3, although DM 
can still catalyze the peptide exchange, the catalytic activity is inefficient. The poor 
catalytic efficiency may relate to unique properties of DQ8 molecules, including the extra 
hydrogen bonds between α and β chain present in DQ8. However, a structural 
explanation for this inefficient DM catalysis needs to be further investigated. It is 
plausible that the extra hydrogen bonds might increase the stability of DQ8-peptide 
complex, which might be already over the range of DM-mediated conformational change, 
therefore the conformation of DQ8 molecules might be “frozen” in that intermediate 
state. On the other side, the binding of high affinity peptide might be insufficient to 
overcome the energy barrier of the extra hydrogen bonds to mediate further 
conformational rearrangement that would promote the dissociation of DM from DQ8. 
Therefore, the DQ8-peptide complex stability would be less dependent on the 
contribution of the bound peptide affinity, even though the high affinity peptide might 
have the advantage to compete with the low affinity peptide. Moreover, the association of 
DM with DQ8 could be further affected by extra factor(s), such as the extra N-terminus 
sequence of bound peptide that might contribute to the binding, and the environment of 
peptide-binding groove in DQ8 that might contribute as well.  Further structural analysis 
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of DQ8, especially the DQ8-E86A mutation with CLIP or T1D-associated auto-antigenic 
peptides, might be able to distinguish these possibilities in the future. 
 Although DM interacts with MHCII near the P1 pocket that interacts with the N-
terminus of peptide, the contribution of the interaction between the peptide-binding 
groove and the C-terminus of the peptide sequence in MHCII-peptide complex stability 
and DM editing sensitivity needs to be emphasized as well. As supported by previous 
reports, the salt bridge formed between the polymorphic residue aspartic acid β57 in DR1 
and DQ isotypes with the C-terminus of the bound peptide have been found linked to be 
protective in T1D [66-71]; moreover, extra interactions between peptides and residues 
outside of peptide-binding groove also contribute, as has been confirmed with two 
peptides differing only at P10 and showing distinct binding affinities in DR1 [72, 73]. 
These factors might cooperatively determine the DM interaction with MHCII and the DM 
editing sensitivity. As we found in Chapter 3, the peptides CKA362 and LEP147 both 
have relatively high binding affinities for DQ6 yet, in the presence of DM,  they have a 
high peptide dissociation rate and they are sensitive to DM editing, results that are 
consistent with previous reports [74-77]. It is plausible that these peptides might have 
undefined properties that can efficiently compete with the indicator peptides to bind to 
DQ6, while not efficiently mediating the conformational change that is resistant to DM 
editing. Further structural, molecular dynamic simulation, and biochemical measurements 
of these peptide complexes with anchor residue replacement might provide more 
information to address this possibility.     
The link of inefficient DM editing with T1D-associated DQ molecules indicates a 
critical role for DM in editing the MHCII presented peptide repertoire that determines the 
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selection and/or activation of autoreactive CD4+ T cells involved in T1D etiology [2, 78, 
79]. It is interesting to note that genetic studies of the limited polymorphisms of DMα 
and DMβ in different populations has implied that specific DM alleles are associated with 
T1D [80-82]. These various findings highlight the possibility that clinical targeting in the 
early stage treatment of T1D to enhance DM function, with short peptides [83] or small 
molecules [84, 85] that mimic DM function, may be worthy of investigation. 
In summary, we distinguished some unique properties of T1D-associated DQ2 
and DQ8 molecules, including extra hydrogen bonds in DQ8 that contribute to inefficient 
DM editing and might affect the peptide repertoire presented by T1D-associated DQ 
molecules. We also ruled out the possibility of DM editing by disruption of specific 
hydrogen bond of the conserved hydrogen network formed between bound peptide and 
MHCII, the previously proposed prevailing hypothesis for the DM catalytic mechanism. 
Our findings provided molecular insights into the potential mechanisms through which 
DQ2 and DQ8 confer high genetic risk for T1D, further supported the reliability of 
genetic screening as a powerful tool in the prediction of T1D and highlighting the 
regulation of DM editing as a potential target for the early stage control of T1D.     
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Figure A.1. Asparagine substitution at position 81 in the DR1 beta chain does not 
affect susceptibility to DM-mediated CLIP release. Expression of DR and CLIP on the 
surface of T2 cells expressing βH81N DR1 molecules in the absence (middle panel) or 
presence (right panel) of DM was measured by flow cytometry with mAbs L243 (DR) 
and CerCLIP (CLIP). A retroviral vector encoding full-length DRβ-H81N was generated 
using pLXSN-DRβ-H81A as a template with primers (DRβ-H81N-F: 5’- 
GGTGGACACCTACTGCAGAaaCAACTACGGGGTTGG -3’) and DRβ-H81N-R: 5’- 
CCAACCCCGTAGTTGttTCTGCAGTAGGTGTCCACC -3’), and the product was 
confirmed by DNA sequencing. T2 cells stably expressing the mutant DR1 heterodimer 




Figure A.2. Replacement of the histidine at position 81 in the DR1 beta chain does 
not change the pH dependence of DM-catalyzed peptide binding. Wild type or mutant 
purified soluble recombinant DR1 molecules (50 nM) were incubated with 1 µM 
biotinylated MAT peptide in the presence or absence of 1µM purified soluble DM in a 
buffer containing 0.2% NP-40 and 40 mM citrate/Na2HPO4 (pH 3.0-7.0), in a total 
volume of 30 µl, for 3 hours at 37oC. Following the incubation, samples were pH 
neutralized and DR-bound peptide was measured using a europium fluoroimmunoassay 
as previously described [1, 2]. No peptide binding was detected under these experimental 
conditions with βN82A DR1, which forms very unstable peptide complexes. 
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Figure B.1. Effects of extra hydrogen bonds on DQ8/peptide complex stability and 
DM editing sensitivity. (A) The FP measurement of peptide dissociation rates and DM 
editing effects between DQ8 wild type and E86A mutation bound with CLIP488 or 
ABP625488 peptides. Data shown are representative of four independent experiments. (B) 
The DM-catalyzed rate enhancements normalized with the interpolated intrinsic peptide 

























































Table B.1. Comparison of the interpolated peptide intrinsic dissociation rates (Kin) 
between DQ8 wild type and E86A mutation that disrupted two of the three extra 
hydrogen bonds. 
 
MHC complex Kin 
Ratio of Kin 
(E86A/WT) 
DQ8-WT-ABP625 1.6 x 10-6  
DQ8-E86A-ABP625 7.4 x 10-6 4.6 
DQ8-WT-CLIP 3.3 x 10-6  
DQ8-E86A-CLIP 2.6 x 10-5 7.7 
  
